Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23274625,recovery,The mean recovery ranged from 99.2 to 104.6% and the matrix effect from 89.3 to 99.5%.,Development and validation of an LC-MS/MS method for the determination of tolvaptan in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23274625/),%,99.2 to 104.6,0,DB00067,Vasopressin
,23274625,matrix effect,The mean recovery ranged from 99.2 to 104.6% and the matrix effect from 89.3 to 99.5%.,Development and validation of an LC-MS/MS method for the determination of tolvaptan in human plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23274625/),%,89.3 to 99.5,1,DB00067,Vasopressin
,2597363,Concentration,Concentration of plasma AVP increased slightly from 3.8 +/- 1.5 pg/ml after induction and increased 3-fold after sternotomy.,Responses of vasopressin release in patients with cardiopulmonary bypass anesthetized with enflurane and morphine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2597363/),[pg] / [ml],3.8,344,DB00067,Vasopressin
,3117068,duration of action,The duration of action of orally administered GTN in the dog depended on the concentration used and was between 15 and 360 min.,[The pharmacology and pharmacokinetics of glycerol-2-nitrate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3117068/),min,15 and 360,1924,DB00067,Vasopressin
,3117068,half-life of elimination,"The half-life of elimination of G-2-N in the rat came to 2 h, and the substance was 100% bioavailable.",[The pharmacology and pharmacokinetics of glycerol-2-nitrate]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3117068/),h,2,1925,DB00067,Vasopressin
,17258819,fast phase,"There was no change in the fast phase of the curves of total radioactivity disappearance from the plasma after the administration of [(3)H]arginine vasopressin (control: 1.51+/-0.17 min, OPC-31260-treated: 1.42+/-0.12 min, n=10).",Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17258819/),min,1.51,2867,DB00067,Vasopressin
,17258819,fast phase,"There was no change in the fast phase of the curves of total radioactivity disappearance from the plasma after the administration of [(3)H]arginine vasopressin (control: 1.51+/-0.17 min, OPC-31260-treated: 1.42+/-0.12 min, n=10).",Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17258819/),min,1.42,2868,DB00067,Vasopressin
,17258819,fast phase of the disappearance curves,"The fast phase of the disappearance curves of intact [(3)H]arginine vasopressin did not change either following the administration of OPC-31260 in a dose of 30 mg/kg p.o. (control: 1.06+/-0.19 min, OPC-31260-treated: 1.00+/-0.15 min, n=6).",Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17258819/),min,1.06,2869,DB00067,Vasopressin
,17258819,fast phase of the disappearance curves,"The fast phase of the disappearance curves of intact [(3)H]arginine vasopressin did not change either following the administration of OPC-31260 in a dose of 30 mg/kg p.o. (control: 1.06+/-0.19 min, OPC-31260-treated: 1.00+/-0.15 min, n=6).",Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17258819/),min,1.00,2870,DB00067,Vasopressin
,17258819,radioactivity,"The slow phase of the biological half-life, which is characteristic for the examined compound, proved to be significantly longer (total radioactivity control: 9.29+/-0.61 min, OPC-31260-treated: 12.33+/-0.42 min, P<0.05, n=10; [(3)H]arginine vasopressin radioactivity: control: 5.96+/-0.58 min, OPC-31260-treated: 8.90+/-0.37 min, P<0.05, n=6).",Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17258819/),min,5.96,2871,DB00067,Vasopressin
,17258819,radioactivity,"The slow phase of the biological half-life, which is characteristic for the examined compound, proved to be significantly longer (total radioactivity control: 9.29+/-0.61 min, OPC-31260-treated: 12.33+/-0.42 min, P<0.05, n=10; [(3)H]arginine vasopressin radioactivity: control: 5.96+/-0.58 min, OPC-31260-treated: 8.90+/-0.37 min, P<0.05, n=6).",Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17258819/),min,8.90,2872,DB00067,Vasopressin
,3379594,bioavailability,"The bioavailability of desmopressin from the 2 x 50-microL dose was 20%, which was significantly greater than the 11% after the 1 x 50-microL (p less than 0.01) and 9% after the 1 x 100-microL (p less than 0.001) doses.",Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379594/),%,20,6006,DB00067,Vasopressin
,3379594,bioavailability,"The bioavailability of desmopressin from the 2 x 50-microL dose was 20%, which was significantly greater than the 11% after the 1 x 50-microL (p less than 0.01) and 9% after the 1 x 100-microL (p less than 0.001) doses.",Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379594/),%,11,6007,DB00067,Vasopressin
,3379594,bioavailability,"The bioavailability of desmopressin from the 2 x 50-microL dose was 20%, which was significantly greater than the 11% after the 1 x 50-microL (p less than 0.01) and 9% after the 1 x 100-microL (p less than 0.001) doses.",Effects of concentration and volume on nasal bioavailability and biological response to desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3379594/),%,9,6008,DB00067,Vasopressin
,7991455,absorption half-life,"The mean absorption half-life was 8.7 and 7.3 min and the mean elimination half-life was 38 and 34.6 min for the intranasal and oral route of administration, respectively.",Pharmacokinetics of DGAVP in plasma following intranasal and oral administration to healthy subjects. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7991455/),min,8.7,9027,DB00067,Vasopressin
,7991455,absorption half-life,"The mean absorption half-life was 8.7 and 7.3 min and the mean elimination half-life was 38 and 34.6 min for the intranasal and oral route of administration, respectively.",Pharmacokinetics of DGAVP in plasma following intranasal and oral administration to healthy subjects. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7991455/),min,7.3,9028,DB00067,Vasopressin
,7991455,elimination half-life,"The mean absorption half-life was 8.7 and 7.3 min and the mean elimination half-life was 38 and 34.6 min for the intranasal and oral route of administration, respectively.",Pharmacokinetics of DGAVP in plasma following intranasal and oral administration to healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7991455/),min,38,9029,DB00067,Vasopressin
,7991455,elimination half-life,"The mean absorption half-life was 8.7 and 7.3 min and the mean elimination half-life was 38 and 34.6 min for the intranasal and oral route of administration, respectively.",Pharmacokinetics of DGAVP in plasma following intranasal and oral administration to healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7991455/),min,34.6,9030,DB00067,Vasopressin
,7991455,relative bioavailability,The bioavailability of orally administered DGAVP was low compared with the intranasally administered drug; the relative bioavailability of oral/nasal administration was 0.7%.,Pharmacokinetics of DGAVP in plasma following intranasal and oral administration to healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7991455/),%,0.7,9031,DB00067,Vasopressin
,10706418,EBAp.o.,"The EBAp.o. values, estimated from pharmacological effects (hemodynamic effect and anti-diuretic effect) after oral administration of 5 microg/kg of AVP were 0.68% to 0.93% and were almost identical with the actual EBAPp.o. value (0.81%).",Bioavailability assessment of arginine-vasopressin (AVP) using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10706418/),%,0.68,10723,DB00067,Vasopressin
,10706418,EBAp.o.,"The EBAp.o. values, estimated from pharmacological effects (hemodynamic effect and anti-diuretic effect) after oral administration of 5 microg/kg of AVP were 0.68% to 0.93% and were almost identical with the actual EBAPp.o. value (0.81%).",Bioavailability assessment of arginine-vasopressin (AVP) using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10706418/),%,0.93,10724,DB00067,Vasopressin
,10706418,EBAPp.o.,"The EBAp.o. values, estimated from pharmacological effects (hemodynamic effect and anti-diuretic effect) after oral administration of 5 microg/kg of AVP were 0.68% to 0.93% and were almost identical with the actual EBAPp.o. value (0.81%).",Bioavailability assessment of arginine-vasopressin (AVP) using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10706418/),%,0.81,10725,DB00067,Vasopressin
,28243060,Terminal elimination half-life,"Terminal elimination half-life was slightly longer in impaired subjects (12 h) as compared to normal subjects (9 h), and clearance was 65% higher in subjects with normal liver function, while urinary excretion was higher in impaired individuals.",Pharmacokinetics of conivaptan use in patients with severe hepatic impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28243060/),h,12,11114,DB00067,Vasopressin
,28243060,Terminal elimination half-life,"Terminal elimination half-life was slightly longer in impaired subjects (12 h) as compared to normal subjects (9 h), and clearance was 65% higher in subjects with normal liver function, while urinary excretion was higher in impaired individuals.",Pharmacokinetics of conivaptan use in patients with severe hepatic impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28243060/),h,9,11115,DB00067,Vasopressin
,20027670,pK(i),"This led to the 2', 4'-difluorophenyl dimethylamide 40, a highly potent (pK(i) =9.2) and selective OT antagonist (>1,000-fold selectivity vs. the human vasopressin receptors V1a, V2, and V1b) with good oral bioavailability (>50%) in the rat and dog.","The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027670/),,9.2,12685,DB00067,Vasopressin
>,20027670,oral bioavailability,"This led to the 2', 4'-difluorophenyl dimethylamide 40, a highly potent (pK(i) =9.2) and selective OT antagonist (>1,000-fold selectivity vs. the human vasopressin receptors V1a, V2, and V1b) with good oral bioavailability (>50%) in the rat and dog.","The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027670/),%,50,12686,DB00067,Vasopressin
,20027670,K(i),Retosiban has sub-nanomolar affinity (K(i) =0.65 nM) for the oxytocin receptor with >1400-fold selectivity over the closely related vasopressin receptors.,"The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027670/),nM,0.65,12687,DB00067,Vasopressin
>,20027670,IC(50),"It has good solubility, low protein binding and has a good Cyp450 profile with no significant inhibition IC(50) >100 µM.","The design of orally bioavailable 2, 5-diketopiperazine oxytocin antagonists: from concept to clinical candidate for premature labor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20027670/),μM,100,12688,DB00067,Vasopressin
,8865375,AeAZ0,"After oral administration of azosemide, the values of AeAZ0 (591 vs 318 micrograms) and CLR (2.22 vs 0.875 mL/min/kg) decreased significantly in the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),μg,591,13975,DB00067,Vasopressin
,8865375,AeAZ0,"After oral administration of azosemide, the values of AeAZ0 (591 vs 318 micrograms) and CLR (2.22 vs 0.875 mL/min/kg) decreased significantly in the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),μg,318,13976,DB00067,Vasopressin
,8865375,CLR,"After oral administration of azosemide, the values of AeAZ0 (591 vs 318 micrograms) and CLR (2.22 vs 0.875 mL/min/kg) decreased significantly in the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),[ml] / [kg·min],2.22,13977,DB00067,Vasopressin
,8865375,CLR,"After oral administration of azosemide, the values of AeAZ0 (591 vs 318 micrograms) and CLR (2.22 vs 0.875 mL/min/kg) decreased significantly in the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),[ml] / [kg·min],0.875,13978,DB00067,Vasopressin
,8865375,urine output,The 12-h urine output per g kidney was also reduced significantly in the water-deprived rats after both i.v. (70.3 vs 24.6 mL) and oral (70.7 and 20.7 mL) administration of azosemide.,Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),ml,70.3,13979,DB00067,Vasopressin
,8865375,urine output,The 12-h urine output per g kidney was also reduced significantly in the water-deprived rats after both i.v. (70.3 vs 24.6 mL) and oral (70.7 and 20.7 mL) administration of azosemide.,Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),ml,24.6,13980,DB00067,Vasopressin
,8865375,urine output,The 12-h urine output per g kidney was also reduced significantly in the water-deprived rats after both i.v. (70.3 vs 24.6 mL) and oral (70.7 and 20.7 mL) administration of azosemide.,Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),ml,70.7,13981,DB00067,Vasopressin
,8865375,urine output,The 12-h urine output per g kidney was also reduced significantly in the water-deprived rats after both i.v. (70.3 vs 24.6 mL) and oral (70.7 and 20.7 mL) administration of azosemide.,Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),ml,20.7,13982,DB00067,Vasopressin
,8865375,urine output,"The 12-h urine output per g kidney of i.v. and oral administration of azosemide in the control rats were similar (70.3 +/- 17.3 vs 70.7 +/- 13.8 mL), although the AeAZ0 after oral administration was significantly smaller than that after i.v. administration (473 +/- 98.5 vs 285 +/- 76.3 micrograms), and similar results were also obtained from the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),ml,70.3,13983,DB00067,Vasopressin
,8865375,urine output,"The 12-h urine output per g kidney of i.v. and oral administration of azosemide in the control rats were similar (70.3 +/- 17.3 vs 70.7 +/- 13.8 mL), although the AeAZ0 after oral administration was significantly smaller than that after i.v. administration (473 +/- 98.5 vs 285 +/- 76.3 micrograms), and similar results were also obtained from the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),ml,70.7,13984,DB00067,Vasopressin
,8865375,AeAZ0,"The 12-h urine output per g kidney of i.v. and oral administration of azosemide in the control rats were similar (70.3 +/- 17.3 vs 70.7 +/- 13.8 mL), although the AeAZ0 after oral administration was significantly smaller than that after i.v. administration (473 +/- 98.5 vs 285 +/- 76.3 micrograms), and similar results were also obtained from the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),μg,473,13985,DB00067,Vasopressin
,8865375,AeAZ0,"The 12-h urine output per g kidney of i.v. and oral administration of azosemide in the control rats were similar (70.3 +/- 17.3 vs 70.7 +/- 13.8 mL), although the AeAZ0 after oral administration was significantly smaller than that after i.v. administration (473 +/- 98.5 vs 285 +/- 76.3 micrograms), and similar results were also obtained from the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),μg,285,13986,DB00067,Vasopressin
,20303469,T(1/2) elimination [T(1/2)el],"A shorter VWF survival was observed in patients with C1130F mutations (T(1/2) elimination [T(1/2)el]=4.6+/-1.0h vs normal=15.8+/-2.3h, P<0.0001), in those with other missense mutations investigated (T(1/2)el=9.5+/-0.9h, P<0.02), and in patients not carrying VWF mutations (T(1/2)el=7.0+/-0.7h, P<0.001); the decrease mainly depended on a greater VWF clearance.",Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20303469/),h,4.6,15345,DB00067,Vasopressin
,20303469,T(1/2) elimination [T(1/2)el],"A shorter VWF survival was observed in patients with C1130F mutations (T(1/2) elimination [T(1/2)el]=4.6+/-1.0h vs normal=15.8+/-2.3h, P<0.0001), in those with other missense mutations investigated (T(1/2)el=9.5+/-0.9h, P<0.02), and in patients not carrying VWF mutations (T(1/2)el=7.0+/-0.7h, P<0.001); the decrease mainly depended on a greater VWF clearance.",Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20303469/),h,15.8,15346,DB00067,Vasopressin
,20303469,T(1/2)el,"A shorter VWF survival was observed in patients with C1130F mutations (T(1/2) elimination [T(1/2)el]=4.6+/-1.0h vs normal=15.8+/-2.3h, P<0.0001), in those with other missense mutations investigated (T(1/2)el=9.5+/-0.9h, P<0.02), and in patients not carrying VWF mutations (T(1/2)el=7.0+/-0.7h, P<0.001); the decrease mainly depended on a greater VWF clearance.",Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20303469/),h,9.5,15347,DB00067,Vasopressin
,20303469,T(1/2)el,"A shorter VWF survival was observed in patients with C1130F mutations (T(1/2) elimination [T(1/2)el]=4.6+/-1.0h vs normal=15.8+/-2.3h, P<0.0001), in those with other missense mutations investigated (T(1/2)el=9.5+/-0.9h, P<0.02), and in patients not carrying VWF mutations (T(1/2)el=7.0+/-0.7h, P<0.001); the decrease mainly depended on a greater VWF clearance.",Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20303469/),h,7.0,15348,DB00067,Vasopressin
,22257581,absolute bioavailability,Mean absolute bioavailability was determined to be 56% (range 42 - 80).,Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22257581/),%,56,16247,DB00067,Vasopressin
,22257581,peak tolvaptan concentration,Mean peak tolvaptan concentration at 1 h (end-of-infusion) was 32.7 (range 18 - 45) ng/ml compared to 231 (range 87 - 410) ng/ml for the oral dose.,Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22257581/),[ng] / [ml],32.7,16248,DB00067,Vasopressin
,22257581,peak tolvaptan concentration,Mean peak tolvaptan concentration at 1 h (end-of-infusion) was 32.7 (range 18 - 45) ng/ml compared to 231 (range 87 - 410) ng/ml for the oral dose.,Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22257581/),[ng] / [ml],231,16249,DB00067,Vasopressin
,3951326,steady-state level,Intravenous infusion of DDAVP (0.13 pmol/l min) resulted in a mean steady-state level of 20.3 pmol/l.,Absorption of intragastrically administered DDAVP in conscious dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3951326/),[pM] / [l],20.3,16985,DB00067,Vasopressin
,3951326,Elimination half-lives,Elimination half-lives for oral DDAVP were 77.6 and 76.1 min for low and high doses respectively.,Absorption of intragastrically administered DDAVP in conscious dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3951326/),min,77.6,16986,DB00067,Vasopressin
,3951326,Elimination half-lives,Elimination half-lives for oral DDAVP were 77.6 and 76.1 min for low and high doses respectively.,Absorption of intragastrically administered DDAVP in conscious dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3951326/),min,76.1,16987,DB00067,Vasopressin
,3951326,T1/2,T1/2 estimated from the ascending part of the i.v. infusion curve was 50 min.,Absorption of intragastrically administered DDAVP in conscious dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3951326/),min,50,16988,DB00067,Vasopressin
,3951326,metabolic clearance rate (MCR),A metabolic clearance rate (MCR) of 3.9 ml/kg . min was assessed from the i.v. steady-state level.,Absorption of intragastrically administered DDAVP in conscious dogs. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3951326/),[ml] / [kg·min],3.9,16989,DB00067,Vasopressin
,16620295,Ki,2. RWJ-351647 displaced (3)H-AVP binding from cloned human V(2) and V(1A) receptors with Ki values of 1 nmol/L and 24 nmol/L.,"Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620295/),[nM] / [l],1,16997,DB00067,Vasopressin
,16620295,Ki,2. RWJ-351647 displaced (3)H-AVP binding from cloned human V(2) and V(1A) receptors with Ki values of 1 nmol/L and 24 nmol/L.,"Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620295/),[nM] / [l],24,16998,DB00067,Vasopressin
,16620295,Ki,"In assays using transfected HEK293 cells expressing either human or rat V(2) receptors, RWJ-351647 inhibited AVP-induced cAMP accumulation with Ki values of 3 nmol/L and 6 nmol/L, respectively.","Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620295/),[nM] / [l],3,16999,DB00067,Vasopressin
,16620295,Ki,"In assays using transfected HEK293 cells expressing either human or rat V(2) receptors, RWJ-351647 inhibited AVP-induced cAMP accumulation with Ki values of 3 nmol/L and 6 nmol/L, respectively.","Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620295/),[nM] / [l],6,17000,DB00067,Vasopressin
,16620295,bioavailable,4. Pharmacokinetic studies in rats showed RWJ-351647 to be 41.9% bioavailable after a single oral administration.,"Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620295/),%,41.9,17001,DB00067,Vasopressin
,16620295,oral bioavailability,"After repeated daily dosing over 5 days, the oral bioavailability remained at 43.9% with no change in the compound peak plasma levels or clearance rate.","Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620295/),%,43.9,17002,DB00067,Vasopressin
,9024262,peak level,"The expected ACTH response to oCRH was enhanced by the concomitant DP administration (peak level, 10.39 +/- 1.12 vs.",Effects of ovine corticotropin-releasing hormone injection and desmopressin coadministration on galanin and adrenocorticotropin plasma levels in normal women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024262/),,10.39,18586,DB00067,Vasopressin
,9024262,integrated ACTH response,"The mean integrated ACTH response, expressed as the area under the curve, to SAL infusion plus oCRH injection vs. that to DP infusion plus oCRH injection was 288.23 +/- 61.94 vs. 699.70 +/- 91.80 pmol/L.60 min, respectively (P < 0.05).",Effects of ovine corticotropin-releasing hormone injection and desmopressin coadministration on galanin and adrenocorticotropin plasma levels in normal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024262/),[pM] / [60·l·min],288.23,18587,DB00067,Vasopressin
,9024262,integrated ACTH response,"The mean integrated ACTH response, expressed as the area under the curve, to SAL infusion plus oCRH injection vs. that to DP infusion plus oCRH injection was 288.23 +/- 61.94 vs. 699.70 +/- 91.80 pmol/L.60 min, respectively (P < 0.05).",Effects of ovine corticotropin-releasing hormone injection and desmopressin coadministration on galanin and adrenocorticotropin plasma levels in normal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024262/),[pM] / [60·l·min],699.70,18588,DB00067,Vasopressin
,9024262,area under the curve,"The mean integrated ACTH response, expressed as the area under the curve, to SAL infusion plus oCRH injection vs. that to DP infusion plus oCRH injection was 288.23 +/- 61.94 vs. 699.70 +/- 91.80 pmol/L.60 min, respectively (P < 0.05).",Effects of ovine corticotropin-releasing hormone injection and desmopressin coadministration on galanin and adrenocorticotropin plasma levels in normal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024262/),[pM] / [60·l·min],288.23,18589,DB00067,Vasopressin
,9024262,area under the curve,"The mean integrated ACTH response, expressed as the area under the curve, to SAL infusion plus oCRH injection vs. that to DP infusion plus oCRH injection was 288.23 +/- 61.94 vs. 699.70 +/- 91.80 pmol/L.60 min, respectively (P < 0.05).",Effects of ovine corticotropin-releasing hormone injection and desmopressin coadministration on galanin and adrenocorticotropin plasma levels in normal women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9024262/),[pM] / [60·l·min],699.70,18590,DB00067,Vasopressin
,17472657,terminal half-life,"After intravenous injection at a dosage of 0.02 mg/kg bw, the terminal half-life was 73.8+/-19.9 min (mean+/-SD), the apparent volume of distribution 5.22+/-1.01 L/kg, and total body clearance 79.1+/-18.5 mL/min/kg.","Clinical pharmacology of buprenorphine in healthy, lactating goats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472657/),min,73.8,19613,DB00067,Vasopressin
,17472657,apparent volume of distribution,"After intravenous injection at a dosage of 0.02 mg/kg bw, the terminal half-life was 73.8+/-19.9 min (mean+/-SD), the apparent volume of distribution 5.22+/-1.01 L/kg, and total body clearance 79.1+/-18.5 mL/min/kg.","Clinical pharmacology of buprenorphine in healthy, lactating goats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472657/),[l] / [kg],5.22,19614,DB00067,Vasopressin
,17472657,total body clearance,"After intravenous injection at a dosage of 0.02 mg/kg bw, the terminal half-life was 73.8+/-19.9 min (mean+/-SD), the apparent volume of distribution 5.22+/-1.01 L/kg, and total body clearance 79.1+/-18.5 mL/min/kg.","Clinical pharmacology of buprenorphine in healthy, lactating goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472657/),[ml] / [kg·min],79.1,19615,DB00067,Vasopressin
,17472657,clearance,"After intramuscular administration of buprenorphine at the same dosage, bioavailability was complete and clearance was 54.7+/-16.6 mL/min/kg.","Clinical pharmacology of buprenorphine in healthy, lactating goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17472657/),[ml] / [kg·min],54.7,19616,DB00067,Vasopressin
,7711446,Elimination constant,"Elimination constant was higher for inulin than for ADH (0.049 +/- 0.001 vs. 0.020 +/- 0.003 min-1, respectively), suggesting reabsorption of the hormone.",Participation of the kidney in the kinetics of arginine vasopressin in the water-loaded rat. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711446/),1/[min],0.049,23531,DB00067,Vasopressin
,7711446,Elimination constant,"Elimination constant was higher for inulin than for ADH (0.049 +/- 0.001 vs. 0.020 +/- 0.003 min-1, respectively), suggesting reabsorption of the hormone.",Participation of the kidney in the kinetics of arginine vasopressin in the water-loaded rat. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7711446/),1/[min],0.020,23532,DB00067,Vasopressin
,6861441,free water reabsorption,"When factored for delivery of solute, however, free water reabsorption decreased from 0.66 +/- 0.02 to 0.61 +/- 0.02, indicating a site of effect of tripamide at the medullary segment of the thick ascending limb of Henle's loop.",Sites of action of tripamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861441/),,0.66,24366,DB00067,Vasopressin
,6861441,free water reabsorption,"When factored for delivery of solute, however, free water reabsorption decreased from 0.66 +/- 0.02 to 0.61 +/- 0.02, indicating a site of effect of tripamide at the medullary segment of the thick ascending limb of Henle's loop.",Sites of action of tripamide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861441/),,0.61,24367,DB00067,Vasopressin
,7205124,biological half-life,"The biological half-life of synthetic, radiochemically pure, biologically active [3H]1-deamino-8-D-arginine-vasopressin (dDAVP) in rats was found to be 5.33 +/- 0.28 (S.E.M.) min in the initial, transitional, fast phase and 56.28 +/- 3.27 min in the second, slow phase.",Biological half-life and organ distribution of [3H]1-deamino-8-D-arginine-vasopressin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205124/),min,5.33,27926,DB00067,Vasopressin
,7205124,biological half-life,"The biological half-life of synthetic, radiochemically pure, biologically active [3H]1-deamino-8-D-arginine-vasopressin (dDAVP) in rats was found to be 5.33 +/- 0.28 (S.E.M.) min in the initial, transitional, fast phase and 56.28 +/- 3.27 min in the second, slow phase.",Biological half-life and organ distribution of [3H]1-deamino-8-D-arginine-vasopressin in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205124/),min,56.28,27927,DB00067,Vasopressin
,10638391,oral bioavailability,YM087 had an oral bioavailability of 44% and a short half-life.,"Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638391/),%,44,30300,DB00067,Vasopressin
,10638391,plasma osmolality,"Simultaneously, significant increases in plasma osmolality (from 283 +/- 1.3 mosmol/l to 288 +/- 1.0 mosmol/l after i.v. and from 283 +/- 2.1 mosmol/l to 289 +/- 1.7-mosmol/l after oral administration) and vasopressin levels (from 1.5 +/- 0.3 pg/ml to 3.7 +/- 0.6 pg/ml after i.v. and from 0.9 +/- 0.1 pg/ml to 3.9 +/- 0.7 pg/ml after oral administration) were found.","Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638391/),[mosmol] / [l],283,30301,DB00067,Vasopressin
,10638391,plasma osmolality,"Simultaneously, significant increases in plasma osmolality (from 283 +/- 1.3 mosmol/l to 288 +/- 1.0 mosmol/l after i.v. and from 283 +/- 2.1 mosmol/l to 289 +/- 1.7-mosmol/l after oral administration) and vasopressin levels (from 1.5 +/- 0.3 pg/ml to 3.7 +/- 0.6 pg/ml after i.v. and from 0.9 +/- 0.1 pg/ml to 3.9 +/- 0.7 pg/ml after oral administration) were found.","Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638391/),[mosmol] / [l],288,30302,DB00067,Vasopressin
,10638391,plasma osmolality,"Simultaneously, significant increases in plasma osmolality (from 283 +/- 1.3 mosmol/l to 288 +/- 1.0 mosmol/l after i.v. and from 283 +/- 2.1 mosmol/l to 289 +/- 1.7-mosmol/l after oral administration) and vasopressin levels (from 1.5 +/- 0.3 pg/ml to 3.7 +/- 0.6 pg/ml after i.v. and from 0.9 +/- 0.1 pg/ml to 3.9 +/- 0.7 pg/ml after oral administration) were found.","Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638391/),[mosmol] / [l],283,30303,DB00067,Vasopressin
,10638391,plasma osmolality,"Simultaneously, significant increases in plasma osmolality (from 283 +/- 1.3 mosmol/l to 288 +/- 1.0 mosmol/l after i.v. and from 283 +/- 2.1 mosmol/l to 289 +/- 1.7-mosmol/l after oral administration) and vasopressin levels (from 1.5 +/- 0.3 pg/ml to 3.7 +/- 0.6 pg/ml after i.v. and from 0.9 +/- 0.1 pg/ml to 3.9 +/- 0.7 pg/ml after oral administration) were found.","Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638391/),[mosmol] / [l],289,30304,DB00067,Vasopressin
,3141199,plasma half-life,There was no effect of the route on the plasma half-life of DDAVP which ranged from 2.7 to 4.6 h.,Pharmacokinetics and haematological effects of desmopressin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141199/),h,2.7 to 4.6,30448,DB00067,Vasopressin
,3141199,bioavailability,"Based on AUC data, bioavailability via the two s.c. methods and the i.n. route was 112%, 94% and 2%, respectively.",Pharmacokinetics and haematological effects of desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141199/),%,112,30449,DB00067,Vasopressin
,3141199,bioavailability,"Based on AUC data, bioavailability via the two s.c. methods and the i.n. route was 112%, 94% and 2%, respectively.",Pharmacokinetics and haematological effects of desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141199/),%,94,30450,DB00067,Vasopressin
,3141199,bioavailability,"Based on AUC data, bioavailability via the two s.c. methods and the i.n. route was 112%, 94% and 2%, respectively.",Pharmacokinetics and haematological effects of desmopressin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3141199/),%,2,30451,DB00067,Vasopressin
,10026839,IC50,"Two previously validated surrogate markers using exogenous vasopressin were sufficient to provide evidence of the V1a antagonistic effects of SR 49059 after the first single oral administration, and during the 7 days of treatment: Ex-vivo AVP induced platelet aggregation inhibition: SR 49059 has shown potent antagonistic properties in inhibiting AVP-induced human platelet aggregation in vitro (IC50 = 3.7 nM).","Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10026839/),nM,3.7,32728,DB00067,Vasopressin
,10026839,t1/2,Steady state SR 49059 levels were achieved on days 4-5 with moderate (1.8-2.4 fold) accumulation (t1/2: 32 hrs).,"Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10026839/),h,32,32729,DB00067,Vasopressin
,10026839,Cmax,Cmax values were in the range 0.8-30 ng/ml.,"Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10026839/),[ng] / [ml],0.8-30,32730,DB00067,Vasopressin
,10026839,IC50,"The IC50 of AVP (50 nM) -induced platelet aggregation and cutaneous blanching effect were 2.1 +/- 0.7 nM (1.3 ng/mL) and 4.6 +/- 2.5 nM (2.8 ng/mL), respectively.","Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10026839/),nM,2.1,32731,DB00067,Vasopressin
,10026839,IC50,"The IC50 of AVP (50 nM) -induced platelet aggregation and cutaneous blanching effect were 2.1 +/- 0.7 nM (1.3 ng/mL) and 4.6 +/- 2.5 nM (2.8 ng/mL), respectively.","Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10026839/),[ng] / [ml],1.3,32732,DB00067,Vasopressin
,10026839,IC50,"The IC50 of AVP (50 nM) -induced platelet aggregation and cutaneous blanching effect were 2.1 +/- 0.7 nM (1.3 ng/mL) and 4.6 +/- 2.5 nM (2.8 ng/mL), respectively.","Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10026839/),nM,4.6,32733,DB00067,Vasopressin
,10026839,IC50,"The IC50 of AVP (50 nM) -induced platelet aggregation and cutaneous blanching effect were 2.1 +/- 0.7 nM (1.3 ng/mL) and 4.6 +/- 2.5 nM (2.8 ng/mL), respectively.","Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10026839/),[ng] / [ml],2.8,32734,DB00067,Vasopressin
,16828890,zeta potential,"CBSA-NPs loaded with NC-1900 in spherical shape and uniform size below 100 nm were prepared by the double emulsion/solvent evaporation procedure, and the zeta potential of CBSA-NPs was about -8mV with the loading capacity of NC-1900 around 0.46%.","Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16828890/),m,-,34040,DB00067,Vasopressin
,16828890,zeta potential,"CBSA-NPs loaded with NC-1900 in spherical shape and uniform size below 100 nm were prepared by the double emulsion/solvent evaporation procedure, and the zeta potential of CBSA-NPs was about -8mV with the loading capacity of NC-1900 around 0.46%.","Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16828890/),m,8,34041,DB00067,Vasopressin
,16828890,loading capacity,"CBSA-NPs loaded with NC-1900 in spherical shape and uniform size below 100 nm were prepared by the double emulsion/solvent evaporation procedure, and the zeta potential of CBSA-NPs was about -8mV with the loading capacity of NC-1900 around 0.46%.","Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16828890/),%,0.46,34042,DB00067,Vasopressin
,16828890,half-life,"Furthermore, the half-life of NC-1900 loaded in CBSA-NPs in plasma was about 78 h, which was 4-fold longer than that of free NC-1900 (19 h).","Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16828890/),h,78,34043,DB00067,Vasopressin
,16828890,half-life,"Furthermore, the half-life of NC-1900 loaded in CBSA-NPs in plasma was about 78 h, which was 4-fold longer than that of free NC-1900 (19 h).","Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16828890/),h,19,34044,DB00067,Vasopressin
,16625986,area under the curve from 0 - 12 h (AUC0-12h),"The area under the curve from 0 - 12 h (AUC0-12h) was 54.66 +/- 25.92 pg x h/ml after the 160 microg dose, 104.38 +/- 79.10 pg x h/ml following the 240 microg dose and 133.18 +/- 181.84 pg x h/ml following the 320 microg dose.",Plasma pharmacokinetics of desmopressin following sublingual administration: an exploratory dose-escalation study in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625986/),[h·pg] / [ml],54.66,36460,DB00067,Vasopressin
,16625986,area under the curve from 0 - 12 h (AUC0-12h),"The area under the curve from 0 - 12 h (AUC0-12h) was 54.66 +/- 25.92 pg x h/ml after the 160 microg dose, 104.38 +/- 79.10 pg x h/ml following the 240 microg dose and 133.18 +/- 181.84 pg x h/ml following the 320 microg dose.",Plasma pharmacokinetics of desmopressin following sublingual administration: an exploratory dose-escalation study in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625986/),[h·pg] / [ml],104.38,36461,DB00067,Vasopressin
,16625986,area under the curve from 0 - 12 h (AUC0-12h),"The area under the curve from 0 - 12 h (AUC0-12h) was 54.66 +/- 25.92 pg x h/ml after the 160 microg dose, 104.38 +/- 79.10 pg x h/ml following the 240 microg dose and 133.18 +/- 181.84 pg x h/ml following the 320 microg dose.",Plasma pharmacokinetics of desmopressin following sublingual administration: an exploratory dose-escalation study in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16625986/),[h·pg] / [ml],133.18,36462,DB00067,Vasopressin
,28134419,Cmax,"The IV and SIO group had a mean Cmax of 68,151 ± SD 21,534 and 69,034 ± SD 40,169 pg/mL, respectively.",The effects of sternal and intravenous vasopressin administration on pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28134419/),[pg] / [ml],"68,151",38330,DB00067,Vasopressin
,28134419,Cmax,"The IV and SIO group had a mean Cmax of 68,151 ± SD 21,534 and 69,034 ± SD 40,169 pg/mL, respectively.",The effects of sternal and intravenous vasopressin administration on pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28134419/),[pg] / [ml],"69,034",38331,DB00067,Vasopressin
,28134419,Tmax,"The IV and SIO vasopressin groups had a mean Tmax of 105 ± SD 39 and 80 ± SD 41 seconds, respectively.",The effects of sternal and intravenous vasopressin administration on pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28134419/),seconds,105,38332,DB00067,Vasopressin
,28134419,Tmax,"The IV and SIO vasopressin groups had a mean Tmax of 105 ± SD 39 and 80 ± SD 41 seconds, respectively.",The effects of sternal and intravenous vasopressin administration on pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28134419/),seconds,80,38333,DB00067,Vasopressin
,8992020,distribution,"After intravenous administration of meclofenamate, the distribution and elimination half-lives of the drug were 7.2 min and 542 min respectively, Vss was 1.68 L/kg and ClB was 2.47 mliter/min kg.",Influence of closure of the reticular groove on the bioavailability and disposition kinetics of meclofenamate in sheep. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992020/),min,7.2,39857,DB00067,Vasopressin
,8992020,elimination half-lives,"After intravenous administration of meclofenamate, the distribution and elimination half-lives of the drug were 7.2 min and 542 min respectively, Vss was 1.68 L/kg and ClB was 2.47 mliter/min kg.",Influence of closure of the reticular groove on the bioavailability and disposition kinetics of meclofenamate in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992020/),min,542,39858,DB00067,Vasopressin
,8992020,Vss,"After intravenous administration of meclofenamate, the distribution and elimination half-lives of the drug were 7.2 min and 542 min respectively, Vss was 1.68 L/kg and ClB was 2.47 mliter/min kg.",Influence of closure of the reticular groove on the bioavailability and disposition kinetics of meclofenamate in sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992020/),[l] / [kg],1.68,39859,DB00067,Vasopressin
,8992020,ClB,"After intravenous administration of meclofenamate, the distribution and elimination half-lives of the drug were 7.2 min and 542 min respectively, Vss was 1.68 L/kg and ClB was 2.47 mliter/min kg.",Influence of closure of the reticular groove on the bioavailability and disposition kinetics of meclofenamate in sheep. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992020/),[mliter] / [kg·min],2.47,39860,DB00067,Vasopressin
,8992020,tmax-1,"When the reticular groove was closed, two peaks were observed (tmax-1 12-15 min, Cmax-1 3.30-24.01 micrograms/mliter; and tmax-2' 52.50-75 min, Cmax-2, 6.45-11.08 micrograms/mliter).",Influence of closure of the reticular groove on the bioavailability and disposition kinetics of meclofenamate in sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992020/),min,12-15,39861,DB00067,Vasopressin
,8992020,Cmax-1,"When the reticular groove was closed, two peaks were observed (tmax-1 12-15 min, Cmax-1 3.30-24.01 micrograms/mliter; and tmax-2' 52.50-75 min, Cmax-2, 6.45-11.08 micrograms/mliter).",Influence of closure of the reticular groove on the bioavailability and disposition kinetics of meclofenamate in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992020/),[μg] / [mliter],3.30-24.01,39862,DB00067,Vasopressin
,8992020,tmax-2',"When the reticular groove was closed, two peaks were observed (tmax-1 12-15 min, Cmax-1 3.30-24.01 micrograms/mliter; and tmax-2' 52.50-75 min, Cmax-2, 6.45-11.08 micrograms/mliter).",Influence of closure of the reticular groove on the bioavailability and disposition kinetics of meclofenamate in sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992020/),min,52.50-75,39863,DB00067,Vasopressin
,8992020,Cmax-2,"When the reticular groove was closed, two peaks were observed (tmax-1 12-15 min, Cmax-1 3.30-24.01 micrograms/mliter; and tmax-2' 52.50-75 min, Cmax-2, 6.45-11.08 micrograms/mliter).",Influence of closure of the reticular groove on the bioavailability and disposition kinetics of meclofenamate in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8992020/),[μg] / [mliter],6.45-11.08,39864,DB00067,Vasopressin
,26686501,urine output,"Despite treatment with vasopressin, his urine output reached 5-6 L/day as a result of the DI, and his CrCl increased to 180-278 mL/min.",Therapeutic Dose Monitoring for Linezolid in a Patient with MRSA Pneumonia with Bacteremia in Diabetes Insipidus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26686501/),[l] / [d],5-6,39930,DB00067,Vasopressin
,26686501,area under the plasma LZD concentration-time curve (AUC)24/minimum inhibitory concentration (MIC),The blood 24-h area under the plasma LZD concentration-time curve (AUC)24/minimum inhibitory concentration (MIC) was 69.3.,Therapeutic Dose Monitoring for Linezolid in a Patient with MRSA Pneumonia with Bacteremia in Diabetes Insipidus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26686501/),,69.3,39931,DB00067,Vasopressin
,7812627,plasma osmolality,"3. In dehydrated and hyperosmolal-hydrated rabbits, plasma osmolality was 321 +/- 1 and 313 +/- 1 mOsm kg-1, respectively (P < 0.01 compared to controls, 285 +/- 1 mOsm kg-1).",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[mosm] / [kg],321,40565,DB00067,Vasopressin
,7812627,plasma osmolality,"3. In dehydrated and hyperosmolal-hydrated rabbits, plasma osmolality was 321 +/- 1 and 313 +/- 1 mOsm kg-1, respectively (P < 0.01 compared to controls, 285 +/- 1 mOsm kg-1).",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[mosm] / [kg],313,40566,DB00067,Vasopressin
,7812627,plasma osmolality,"3. In dehydrated and hyperosmolal-hydrated rabbits, plasma osmolality was 321 +/- 1 and 313 +/- 1 mOsm kg-1, respectively (P < 0.01 compared to controls, 285 +/- 1 mOsm kg-1).",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[mosm] / [kg],285,40567,DB00067,Vasopressin
,7812627,systemic clearance,"4. Under both experimental conditions, lignocaine plasma concentrations were almost double (P < 0.01) those in controls, due to a lower systemic clearance, e.g. 54 +/- 3 and 59 +/- 1 vs. 96 +/- 5 ml min-1 kg-1, respectively.",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [kg·min],54,40568,DB00067,Vasopressin
,7812627,systemic clearance,"4. Under both experimental conditions, lignocaine plasma concentrations were almost double (P < 0.01) those in controls, due to a lower systemic clearance, e.g. 54 +/- 3 and 59 +/- 1 vs. 96 +/- 5 ml min-1 kg-1, respectively.",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [kg·min],59,40569,DB00067,Vasopressin
,7812627,systemic clearance,"4. Under both experimental conditions, lignocaine plasma concentrations were almost double (P < 0.01) those in controls, due to a lower systemic clearance, e.g. 54 +/- 3 and 59 +/- 1 vs. 96 +/- 5 ml min-1 kg-1, respectively.",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [kg·min],96,40570,DB00067,Vasopressin
,7812627,hepatic plasma flow,AVP reduced hepatic plasma flow from 38.9 +/-2.7 ml min-1 to 19.6 +/-2.5 ml min-1 (P<0.01).,Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [min],38.9,40571,DB00067,Vasopressin
,7812627,hepatic plasma flow,AVP reduced hepatic plasma flow from 38.9 +/-2.7 ml min-1 to 19.6 +/-2.5 ml min-1 (P<0.01).,Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[ml] / [min],19.6,40572,DB00067,Vasopressin
,7812627,Emax,"The predicted maximal AVP-induced decrease in hepatic plasma flow was 19.6 ml min-1 kg- 1(Emax), and AVP concentration eliciting 50% of Em.. (ED50) was 28.7 pg ml-1.6",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[1·kg-·ml] / [min],19.6,40573,DB00067,Vasopressin
,7812627,Em.. (,"The predicted maximal AVP-induced decrease in hepatic plasma flow was 19.6 ml min-1 kg- 1(Emax), and AVP concentration eliciting 50% of Em.. (ED50) was 28.7 pg ml-1.6",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[pg] / [ml],28.7,40574,DB00067,Vasopressin
,7812627,ED50),"The predicted maximal AVP-induced decrease in hepatic plasma flow was 19.6 ml min-1 kg- 1(Emax), and AVP concentration eliciting 50% of Em.. (ED50) was 28.7 pg ml-1.6",Effect of dehydration and hyperosmolal hydration on lignocaine and metabolites disposition in conscious rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7812627/),[pg] / [ml],28.7,40575,DB00067,Vasopressin
,10948696,terminal half-lives of elimination (t1/2 beta),The calculated terminal half-lives of elimination (t1/2 beta) ranged between 2.76 and 8.37 hr with an overall mean of 4.36 hr.,Indirect-response modeling of desmopressin at different levels of hydration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10948696/),h,2.76 and 8.37,40947,DB00067,Vasopressin
,10948696,terminal half-lives of elimination (t1/2 beta),The calculated terminal half-lives of elimination (t1/2 beta) ranged between 2.76 and 8.37 hr with an overall mean of 4.36 hr.,Indirect-response modeling of desmopressin at different levels of hydration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10948696/),h,4.36,40948,DB00067,Vasopressin
,10948696,plasma clearance,"The overall means of plasma clearance and the volumes of distribution of the central compartment (Vc) and at steady state (Vss) were estimated to be 1.34 (SD 0.35) ml.min-1.kg-1, 151 (SD28) ml.kg-1, and 386 (SD 63) ml.kg-1, respectively.",Indirect-response modeling of desmopressin at different levels of hydration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10948696/),[ml] / [kg·min],1.34,40949,DB00067,Vasopressin
,10948696,volumes of distribution of the central compartment (Vc),"The overall means of plasma clearance and the volumes of distribution of the central compartment (Vc) and at steady state (Vss) were estimated to be 1.34 (SD 0.35) ml.min-1.kg-1, 151 (SD28) ml.kg-1, and 386 (SD 63) ml.kg-1, respectively.",Indirect-response modeling of desmopressin at different levels of hydration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10948696/),[ml] / [kg],151,40950,DB00067,Vasopressin
,10948696,at steady state (Vss),"The overall means of plasma clearance and the volumes of distribution of the central compartment (Vc) and at steady state (Vss) were estimated to be 1.34 (SD 0.35) ml.min-1.kg-1, 151 (SD28) ml.kg-1, and 386 (SD 63) ml.kg-1, respectively.",Indirect-response modeling of desmopressin at different levels of hydration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10948696/),[ml] / [kg],386,40951,DB00067,Vasopressin
,10948696,IC50,"The mean values for IC50 and the sigmodicity factor (gamma) were 3.7 (SD 1.2) pg ml-1 and 13.0 (SD 3.5), respectively.",Indirect-response modeling of desmopressin at different levels of hydration. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10948696/),[pg] / [ml],3.7,40952,DB00067,Vasopressin
,10948696,factor,"The mean values for IC50 and the sigmodicity factor (gamma) were 3.7 (SD 1.2) pg ml-1 and 13.0 (SD 3.5), respectively.",Indirect-response modeling of desmopressin at different levels of hydration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10948696/),[pg] / [ml],3.7,40953,DB00067,Vasopressin
,10948696,factor,"The mean values for IC50 and the sigmodicity factor (gamma) were 3.7 (SD 1.2) pg ml-1 and 13.0 (SD 3.5), respectively.",Indirect-response modeling of desmopressin at different levels of hydration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10948696/),,13.0,40954,DB00067,Vasopressin
,3943491,steady state plasma AVT levels,"Successive 1-h infusions of synthetic AVT (n = 8) at rates of 1.0 and 2.0 ng/min X kg resulted in steady state plasma AVT levels of 30 +/- 7 and 59 +/- 12 pg/ml, respectively.",Changes in steady state plasma arginine vasotocin levels affect ovine fetal renal and cardiovascular function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943491/),[pg] / [ml],30,42691,DB00067,Vasopressin
,3943491,steady state plasma AVT levels,"Successive 1-h infusions of synthetic AVT (n = 8) at rates of 1.0 and 2.0 ng/min X kg resulted in steady state plasma AVT levels of 30 +/- 7 and 59 +/- 12 pg/ml, respectively.",Changes in steady state plasma arginine vasotocin levels affect ovine fetal renal and cardiovascular function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943491/),[pg] / [ml],59,42692,DB00067,Vasopressin
,3943491,clearance rates,"Plasma and urinary AVT clearance rates (45 +/- 8.4 ml/min X kg and 0.38 +/- 0.13 ml/min, respectively) remained constant over the observed range of plasma AVT levels.",Changes in steady state plasma arginine vasotocin levels affect ovine fetal renal and cardiovascular function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943491/),[ml] / [kg·min],45,42693,DB00067,Vasopressin
,3943491,clearance rates,"Plasma and urinary AVT clearance rates (45 +/- 8.4 ml/min X kg and 0.38 +/- 0.13 ml/min, respectively) remained constant over the observed range of plasma AVT levels.",Changes in steady state plasma arginine vasotocin levels affect ovine fetal renal and cardiovascular function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3943491/),[ml] / [min],0.38,42694,DB00067,Vasopressin
,5824107,half-life,"The median half-life of oxytocin after a single injection of 2 u. was 3.2 min (2.0-5.7, 95% confidence limits); this increased significantly (P < 0.01) to 4.8 min (4.4-6.1) when the hormone was infused at a rate of 500 m-u./min.","The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5824107/),min,3.2,46590,DB00067,Vasopressin
,5824107,half-life,"The median half-life of oxytocin after a single injection of 2 u. was 3.2 min (2.0-5.7, 95% confidence limits); this increased significantly (P < 0.01) to 4.8 min (4.4-6.1) when the hormone was infused at a rate of 500 m-u./min.","The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5824107/),min,4.8,46591,DB00067,Vasopressin
,5824107,half-life,"8-lysine vasopressin (LVP), the half-life was 5.7 min (3.6-6.0).","The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5824107/),min,5.7,46592,DB00067,Vasopressin
,5824107,half-lives,"Continuous infusions of the hormones at a rate of 120 m-u./min yielded half-lives of 5.5 min (5.0-7.1) for LVP, and 5.6 min (3.9-9.5) for 8-arginine vasopressin (AVP).","The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5824107/),min,5.5,46593,DB00067,Vasopressin
,5824107,half-lives,"Continuous infusions of the hormones at a rate of 120 m-u./min yielded half-lives of 5.5 min (5.0-7.1) for LVP, and 5.6 min (3.9-9.5) for 8-arginine vasopressin (AVP).","The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5824107/),min,5.6,46594,DB00067,Vasopressin
,5824107,clearance,"In accordance with its shorter half-life, the clearance of oxytocin was greater than that of the vasopressins (1.5 l./min, compared with 1.0 l./min).","The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5824107/),[l] / [min],1.5,46595,DB00067,Vasopressin
,5824107,clearance,"In accordance with its shorter half-life, the clearance of oxytocin was greater than that of the vasopressins (1.5 l./min, compared with 1.0 l./min).","The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/5824107/),[l] / [min],1.0,46596,DB00067,Vasopressin
,3758654,urinary clearance rate,Based on analysis of the amount of DDAVP excreted in the urine the urinary clearance rate was estimated to be 0.10 ml/min/kg body wt.,Biological effect and plasma concentrations of DDAVP after intranasal and peroral administration to humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3758654/),[ml] / [body·kg·min·wt],0.10,47848,DB00067,Vasopressin
,10424324,time to reach Cmax (tmax),"However, significant (P < 0.05) changes in the time to reach Cmax (tmax) values (median and range) were observed as, compared with administration of desmopressin alone (1.3 h and 0.5-4.0), it was longer after pretreatment with loperamide (2.0 h and 0.5-3.0) and shorter following pre-treatment with erythromycin (0.9 h and 0.5-1.3).",Changes in gastrointestinal motility influence the absorption of desmopressin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424324/),h,1.3,47854,DB00067,Vasopressin
,10424324,time to reach Cmax (tmax),"However, significant (P < 0.05) changes in the time to reach Cmax (tmax) values (median and range) were observed as, compared with administration of desmopressin alone (1.3 h and 0.5-4.0), it was longer after pretreatment with loperamide (2.0 h and 0.5-3.0) and shorter following pre-treatment with erythromycin (0.9 h and 0.5-1.3).",Changes in gastrointestinal motility influence the absorption of desmopressin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424324/),,0.5-4.0,47855,DB00067,Vasopressin
,10424324,time to reach Cmax (tmax),"However, significant (P < 0.05) changes in the time to reach Cmax (tmax) values (median and range) were observed as, compared with administration of desmopressin alone (1.3 h and 0.5-4.0), it was longer after pretreatment with loperamide (2.0 h and 0.5-3.0) and shorter following pre-treatment with erythromycin (0.9 h and 0.5-1.3).",Changes in gastrointestinal motility influence the absorption of desmopressin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424324/),h,2.0,47856,DB00067,Vasopressin
,10424324,time to reach Cmax (tmax),"However, significant (P < 0.05) changes in the time to reach Cmax (tmax) values (median and range) were observed as, compared with administration of desmopressin alone (1.3 h and 0.5-4.0), it was longer after pretreatment with loperamide (2.0 h and 0.5-3.0) and shorter following pre-treatment with erythromycin (0.9 h and 0.5-1.3).",Changes in gastrointestinal motility influence the absorption of desmopressin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424324/),,0.5-3.0,47857,DB00067,Vasopressin
,10424324,time to reach Cmax (tmax),"However, significant (P < 0.05) changes in the time to reach Cmax (tmax) values (median and range) were observed as, compared with administration of desmopressin alone (1.3 h and 0.5-4.0), it was longer after pretreatment with loperamide (2.0 h and 0.5-3.0) and shorter following pre-treatment with erythromycin (0.9 h and 0.5-1.3).",Changes in gastrointestinal motility influence the absorption of desmopressin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424324/),h,0.9,47858,DB00067,Vasopressin
,10424324,time to reach Cmax (tmax),"However, significant (P < 0.05) changes in the time to reach Cmax (tmax) values (median and range) were observed as, compared with administration of desmopressin alone (1.3 h and 0.5-4.0), it was longer after pretreatment with loperamide (2.0 h and 0.5-3.0) and shorter following pre-treatment with erythromycin (0.9 h and 0.5-1.3).",Changes in gastrointestinal motility influence the absorption of desmopressin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424324/),,0.5-1.3,47859,DB00067,Vasopressin
,24797719,clearance,"Final population estimates for clearance, volume of distribution, and baseline cortisol concentration were 20.2 L/hr, 244 L, and 1.37 ng/mL, respectively.",Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24797719/),[l] / [h],20.2,53725,DB00067,Vasopressin
,24797719,volume of distribution,"Final population estimates for clearance, volume of distribution, and baseline cortisol concentration were 20.2 L/hr, 244 L, and 1.37 ng/mL, respectively.",Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24797719/),l,244,53726,DB00067,Vasopressin
,24797719,volume of distribution,"Final population estimates for clearance, volume of distribution, and baseline cortisol concentration were 20.2 L/hr, 244 L, and 1.37 ng/mL, respectively.",Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24797719/),[ng] / [ml],1.37,53727,DB00067,Vasopressin
,24797719,unbound hydro,"Using the median weight and postmenstrual age of our subjects (i.e., 1.2 kg and 28 wk) in the final model, the typical unbound hydrocortisone clearance and volume of distribution were 1.0 L/hr and 4.2 L, respectively.",Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24797719/),[l] / [h],1.0,53728,DB00067,Vasopressin
,24797719,clearance,"Using the median weight and postmenstrual age of our subjects (i.e., 1.2 kg and 28 wk) in the final model, the typical unbound hydrocortisone clearance and volume of distribution were 1.0 L/hr and 4.2 L, respectively.",Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24797719/),[l] / [h],1.0,53729,DB00067,Vasopressin
,24797719,volume of distribution,"Using the median weight and postmenstrual age of our subjects (i.e., 1.2 kg and 28 wk) in the final model, the typical unbound hydrocortisone clearance and volume of distribution were 1.0 L/hr and 4.2 L, respectively.",Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24797719/),l,4.2,53730,DB00067,Vasopressin
,24797719,half-life,The typical half-life for unbound hydrocortisone was 2.9 hours.,Population pharmacokinetics of unbound hydrocortisone in critically ill neonates and infants with vasopressor-resistant hypotension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24797719/),h,2.9,53731,DB00067,Vasopressin
,12392842,half-lives,"Pharmacokinetics were similar in normal and HF sheep with half-lives approximating 1.3 and 19.5 h for the first and second phases, respectively.","Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392842/),h,1.3,55876,DB00067,Vasopressin
,12392842,half-lives,"Pharmacokinetics were similar in normal and HF sheep with half-lives approximating 1.3 and 19.5 h for the first and second phases, respectively.","Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392842/),h,19.5,55877,DB00067,Vasopressin
,28814338,nausea behaviour score,The onset of nausea-like behaviour in the placebo-treated group occurred at t3.5h and peaked at t4.75h with nausea behaviour score of 58.5 ± 4.6 mm.,"Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),,58.5,57067,DB00067,Vasopressin
,28814338,terminal half-lives,"The terminal half-lives (harmonic mean ± pseudo SD) for ondansetron, maropitant and metoclopramide were 1.21 ± 0.51, 5.62 ± 0.77 and 0.87 ± 0.17 h respectively.","Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),h,1.21,57068,DB00067,Vasopressin
,28814338,terminal half-lives,"The terminal half-lives (harmonic mean ± pseudo SD) for ondansetron, maropitant and metoclopramide were 1.21 ± 0.51, 5.62 ± 0.77 and 0.87 ± 0.17 h respectively.","Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),h,5.62,57069,DB00067,Vasopressin
,28814338,terminal half-lives,"The terminal half-lives (harmonic mean ± pseudo SD) for ondansetron, maropitant and metoclopramide were 1.21 ± 0.51, 5.62 ± 0.77 and 0.87 ± 0.17 h respectively.","Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28814338/),h,0.87,57070,DB00067,Vasopressin
,12710188,excreted water fraction,"This resulted in diuresis at the peak of which the excreted water fraction reached 23% in rats and 12.4% in human subjects, whereas excretion of the osmotically free water amounted to 0.103 +/- 0.018 ml/min/100 g body weight and 10.0 +/- 1.8 ml/min/1.73 m2 of the body surface, respectively.",[Antidiuretic reaction of the human and rat kidney to peroral administration of arginine-vasopressin and desmopressin]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12710188/),%,23,63645,DB00067,Vasopressin
,12710188,excreted water fraction,"This resulted in diuresis at the peak of which the excreted water fraction reached 23% in rats and 12.4% in human subjects, whereas excretion of the osmotically free water amounted to 0.103 +/- 0.018 ml/min/100 g body weight and 10.0 +/- 1.8 ml/min/1.73 m2 of the body surface, respectively.",[Antidiuretic reaction of the human and rat kidney to peroral administration of arginine-vasopressin and desmopressin]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12710188/),%,12.4,63646,DB00067,Vasopressin
,12710188,excretion,"This resulted in diuresis at the peak of which the excreted water fraction reached 23% in rats and 12.4% in human subjects, whereas excretion of the osmotically free water amounted to 0.103 +/- 0.018 ml/min/100 g body weight and 10.0 +/- 1.8 ml/min/1.73 m2 of the body surface, respectively.",[Antidiuretic reaction of the human and rat kidney to peroral administration of arginine-vasopressin and desmopressin]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12710188/),[ml] / [100·g·min],0.103,63647,DB00067,Vasopressin
,12710188,excretion,"This resulted in diuresis at the peak of which the excreted water fraction reached 23% in rats and 12.4% in human subjects, whereas excretion of the osmotically free water amounted to 0.103 +/- 0.018 ml/min/100 g body weight and 10.0 +/- 1.8 ml/min/1.73 m2 of the body surface, respectively.",[Antidiuretic reaction of the human and rat kidney to peroral administration of arginine-vasopressin and desmopressin]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12710188/),[ml] / [1.73·m2·min],10.0,63648,DB00067,Vasopressin
,3158689,cardiac output,"MDL 17,043 acutely increased cardiac output from 3.6 +/- 0.9 to 4.6 +/- 1.0 liters/min (+28%, p less than 0.001) and decreased mean pulmonary artery wedge pressure from 24 +/- 8 to 13 +/- 8 mm Hg (-46%, p less than 0.001), mean right atrial pressure from 10 +/- 5 to 4 +/- 4 mm Hg (-60%, p less than 0.001) and mean arterial pressure from 78 +/- 9 to 70 +/- 11 mm Hg (-10%, p less than 0.001).","MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158689/),[l] / [min],3.6,64138,DB00067,Vasopressin
,3158689,cardiac output,"MDL 17,043 acutely increased cardiac output from 3.6 +/- 0.9 to 4.6 +/- 1.0 liters/min (+28%, p less than 0.001) and decreased mean pulmonary artery wedge pressure from 24 +/- 8 to 13 +/- 8 mm Hg (-46%, p less than 0.001), mean right atrial pressure from 10 +/- 5 to 4 +/- 4 mm Hg (-60%, p less than 0.001) and mean arterial pressure from 78 +/- 9 to 70 +/- 11 mm Hg (-10%, p less than 0.001).","MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158689/),[l] / [min],4.6,64139,DB00067,Vasopressin
,3158689,Elimination half-life,"Elimination half-life for MDL 17,043 was approximately 20 hours.","MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3158689/),h,20,64140,DB00067,Vasopressin
,31830691,maximum concentration (CMAX),"Pharmacokinetic parameters, determined by PKSolver excel add-in, demonstrated an average maximum concentration (CMAX) of 63.3 pg/mL at 3.5 min after intranasal dose administration.",Short communication: pharmacokinetics of oxytocin administered intranasally to beef cattle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31830691/),[pg] / [ml],63.3,66120,DB00067,Vasopressin
,31830691,half-life (T1/2),An average half-life (T1/2) of 12.1 min after intranasal administration was determined.,Short communication: pharmacokinetics of oxytocin administered intranasally to beef cattle. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31830691/),min,12.1,66121,DB00067,Vasopressin
,2146819,half-life period,"The content of alpha-atriopeptins in the plasma varies approximately between 4 and 12 pmol/l in the course of 24 hours, the half-life period amounts to 1 to 2 min.","[Various recent findings concerning the formation, mechanism of action and significance of atrial natriuretic peptides (atriopeptins)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2146819/),min,1 to 2,66386,DB00067,Vasopressin
,2086166,half-life of distribution,"The half-life of distribution and elimination was 8 and 50 min, respectively.",Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086166/),min,8,68014,DB00067,Vasopressin
,2086166,elimination,"The half-life of distribution and elimination was 8 and 50 min, respectively.",Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086166/),min,50,68015,DB00067,Vasopressin
,2086166,volume of distribution,The volume of distribution was 0.7 l/kg b.wt. and the plasma clearance 9 ml/kg b.wt./min.,Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086166/),[l] / [b·kg·wt],0.7,68016,DB00067,Vasopressin
,2086166,plasma clearance,The volume of distribution was 0.7 l/kg b.wt. and the plasma clearance 9 ml/kg b.wt./min.,Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2086166/),[ml] / [·b·kg·min·wt],9,68017,DB00067,Vasopressin
,8359185,half-life of elimination,"After i.v. administration, the half-life of elimination of dDAVP was 60.0 min, plasma clearance 1.7 ml.min-1.kg-1, amount excreted in urine 2.0 micrograms and renal clearance was 0.8 ml.min-1.kg-1.",Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359185/),min,60.0,69427,DB00067,Vasopressin
,8359185,plasma clearance,"After i.v. administration, the half-life of elimination of dDAVP was 60.0 min, plasma clearance 1.7 ml.min-1.kg-1, amount excreted in urine 2.0 micrograms and renal clearance was 0.8 ml.min-1.kg-1.",Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359185/),[ml] / [kg·min],1.7,69428,DB00067,Vasopressin
,8359185,amount excreted in urine,"After i.v. administration, the half-life of elimination of dDAVP was 60.0 min, plasma clearance 1.7 ml.min-1.kg-1, amount excreted in urine 2.0 micrograms and renal clearance was 0.8 ml.min-1.kg-1.",Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359185/),μg,2.0,69429,DB00067,Vasopressin
,8359185,renal clearance,"After i.v. administration, the half-life of elimination of dDAVP was 60.0 min, plasma clearance 1.7 ml.min-1.kg-1, amount excreted in urine 2.0 micrograms and renal clearance was 0.8 ml.min-1.kg-1.",Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359185/),[ml] / [kg·min],0.8,69430,DB00067,Vasopressin
,8359185,bioavailability (f),The mean bioavailability (f) after gastric application was 0.19% (range 0.02-0.35%).,Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359185/),%,0.19,69431,DB00067,Vasopressin
,8359185,f,"f was 0.24% after duodenal application (range 0.04-0.62%), 0.19% after jejunal (range 0.01-0.41%), 0.03% after distal ileal (range 0.01-0.08%), 0.04% after proximal colonic (range 0.01-0.12%) and 0.04% after rectal (0.01-0.10%) application.",Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359185/),%,0,69432,DB00067,Vasopressin
,8359185,f,"f was 0.24% after duodenal application (range 0.04-0.62%), 0.19% after jejunal (range 0.01-0.41%), 0.03% after distal ileal (range 0.01-0.08%), 0.04% after proximal colonic (range 0.01-0.12%) and 0.04% after rectal (0.01-0.10%) application.",Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359185/),%,0.19,69433,DB00067,Vasopressin
,8359185,f,"f was 0.24% after duodenal application (range 0.04-0.62%), 0.19% after jejunal (range 0.01-0.41%), 0.03% after distal ileal (range 0.01-0.08%), 0.04% after proximal colonic (range 0.01-0.12%) and 0.04% after rectal (0.01-0.10%) application.",Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359185/),%,0.03,69434,DB00067,Vasopressin
,8359185,f,"f was 0.24% after duodenal application (range 0.04-0.62%), 0.19% after jejunal (range 0.01-0.41%), 0.03% after distal ileal (range 0.01-0.08%), 0.04% after proximal colonic (range 0.01-0.12%) and 0.04% after rectal (0.01-0.10%) application.",Absolute bioavailability of an aqueous solution of 1-deamino-8-D-arginine vasopressin from different regions of the gastrointestinal tract in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8359185/),%,0.04,69435,DB00067,Vasopressin
,29198064,half maximal inhibitory concentration,The half maximal inhibitory concentration for inhibition of urine production was 0.7 pg/mL lower for the lyophilisate than for the tablet.,Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29198064/),[pg] / [ml],0.7,75379,DB00067,Vasopressin
,32694360,total run time,The total run time was approximately 5 minutes.,A Novel Quantitative Method for Analyzing Desmopressin in Human Plasma Using Liquid Chromatography-Tandem Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32694360/),min,5,77267,DB00067,Vasopressin
,9695722,apparent volume of distribution,"Kinetics were characterized by a high apparent volume of distribution (43.7 +/- 11.2 L), a high total body clearance (5383 +/- 581 ml/min), and a short plasma half-life (5.57 +/- 0.8 minutes).",Metabolism and action of urodilatin infusion in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695722/),l,43.7,77615,DB00067,Vasopressin
,9695722,total body clearance,"Kinetics were characterized by a high apparent volume of distribution (43.7 +/- 11.2 L), a high total body clearance (5383 +/- 581 ml/min), and a short plasma half-life (5.57 +/- 0.8 minutes).",Metabolism and action of urodilatin infusion in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695722/),[ml] / [min],5383,77616,DB00067,Vasopressin
,9695722,plasma half-life,"Kinetics were characterized by a high apparent volume of distribution (43.7 +/- 11.2 L), a high total body clearance (5383 +/- 581 ml/min), and a short plasma half-life (5.57 +/- 0.8 minutes).",Metabolism and action of urodilatin infusion in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695722/),min,5.57,77617,DB00067,Vasopressin
,9695722,maximal plasma urodilatin level,The maximal plasma urodilatin level was 177.2 +/- 25.8 pmol/L. Less than 1% of total infused urodilatin was recovered in urine.,Metabolism and action of urodilatin infusion in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9695722/),[pM] / [l],177.2,77618,DB00067,Vasopressin
,1441871,maximum venous plasma concentrations,The mean maximum venous plasma concentrations of mepivacaine were more than twice as high as when prilocaine was used as anaesthetic (5.1 micrograms/ml vs. 2.37 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],5.1,79761,DB00067,Vasopressin
,1441871,maximum venous plasma concentrations,The mean maximum venous plasma concentrations of mepivacaine were more than twice as high as when prilocaine was used as anaesthetic (5.1 micrograms/ml vs. 2.37 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],2.37,79762,DB00067,Vasopressin
exceeded,1441871,peak plasma concentrations,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],5,79763,DB00067,Vasopressin
,1441871,peak plasma concentrations,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[mg] / [ml],7.21,79764,DB00067,Vasopressin
,1441871,peak plasma concentrations,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],8.61,79765,DB00067,Vasopressin
,1441871,maximum,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[mg] / [ml],7.21,79766,DB00067,Vasopressin
,1441871,maximum,The peak plasma concentrations exceeded the threshold of 5 micrograms/ml in four of the nine patients of the mepivacaine group (maximum value 7.21 mg/ml) and in two of the nine patients of the mepivacaine+ornipressin group (maximum value 8.61 micrograms/ml).,Plasma prilocaine and mepivacaine concentrations after combined lumbosacral plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1441871/),[μg] / [ml],8.61,79767,DB00067,Vasopressin
,8385161,plasma half-life (t1/2),"The mean (+/- standard error of the mean) plasma half-life (t1/2) of the alpha phase ranged from 1.31 +/- 0.11 to 1.78 +/- 0.15 hours, and the mean t1/2 of the beta phase ranged from 4.31 +/- 0.28 to 6.28 +/- 0.59 hours.","Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptide orally active vasopressin V1 receptor antagonist, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8385161/),h,1.31,87209,DB00067,Vasopressin
,8385161,plasma half-life (t1/2),"The mean (+/- standard error of the mean) plasma half-life (t1/2) of the alpha phase ranged from 1.31 +/- 0.11 to 1.78 +/- 0.15 hours, and the mean t1/2 of the beta phase ranged from 4.31 +/- 0.28 to 6.28 +/- 0.59 hours.","Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptide orally active vasopressin V1 receptor antagonist, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8385161/),h,1.78,87210,DB00067,Vasopressin
,8385161,t1/2,"The mean (+/- standard error of the mean) plasma half-life (t1/2) of the alpha phase ranged from 1.31 +/- 0.11 to 1.78 +/- 0.15 hours, and the mean t1/2 of the beta phase ranged from 4.31 +/- 0.28 to 6.28 +/- 0.59 hours.","Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptide orally active vasopressin V1 receptor antagonist, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8385161/),h,4.31,87211,DB00067,Vasopressin
,8385161,t1/2,"The mean (+/- standard error of the mean) plasma half-life (t1/2) of the alpha phase ranged from 1.31 +/- 0.11 to 1.78 +/- 0.15 hours, and the mean t1/2 of the beta phase ranged from 4.31 +/- 0.28 to 6.28 +/- 0.59 hours.","Pharmacokinetics, safety, and pharmacologic effects of OPC-21268, a nonpeptide orally active vasopressin V1 receptor antagonist, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8385161/),h,6.28,87212,DB00067,Vasopressin
,32935287,time to steady state,"Itraconazole 200 mg/day elevated steady-state exposure to 5 mg/day balovaptan approximately 4.5-5.5-fold (Day 15 GMR [90% CI], 4.46 [4.06-4.90] for Cmax and 5.57 [5.00-6.21] for AUC) and extended the time to steady state from ~ 5 days to ~ 13-14 days.",Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935287/),d,5,87831,DB00067,Vasopressin
,32935287,time to steady state,"Itraconazole 200 mg/day elevated steady-state exposure to 5 mg/day balovaptan approximately 4.5-5.5-fold (Day 15 GMR [90% CI], 4.46 [4.06-4.90] for Cmax and 5.57 [5.00-6.21] for AUC) and extended the time to steady state from ~ 5 days to ~ 13-14 days.",Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32935287/),d,13-14,87832,DB00067,Vasopressin
,950263,Uosm,"3. Maximal ""peak"" response was obtained after an intravenous dose of 1 mug within the first 12 hrs (Uosm was 7--800 mOsm/KgH2O).",The antidiuretic action of 1-deamino-8-D-arginine vasopressin (DDAVP) in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/950263/),[mosm] / [kgh2o],7,88015,DB00067,Vasopressin
above,3618082,ratio urine osmolality/plasma osmolality,"At 12 h after administration, the ratio urine osmolality/plasma osmolality was above 1 only after 20 micrograms intranasally and 400 micrograms perorally.",Central diabetes insipidus in children. Antidiuretic effect and pharmacokinetics of intranasal and peroral 1-deamino-8-D-arginine vasopressin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3618082/),,1,90406,DB00067,Vasopressin
>,16250654,pK(i),Varying the functionality and substitution pattern of substituents in the 7-aryl ring and varying the chirality of this exocyclic ring have produced potent oxytocin antagonists (pK(i) > 8.5).,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16250654/),,8.5,91938,DB00067,Vasopressin
,16250654,bioavailability,It has good bioavailability (46%) in the rat and moderate bioavailability (13-31%) in the dog and is more active in vivo in the rat than atosiban (rat DR(10) = 0.44 mg/kg iv).,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16250654/),%,46,91939,DB00067,Vasopressin
,16250654,bioavailability,It has good bioavailability (46%) in the rat and moderate bioavailability (13-31%) in the dog and is more active in vivo in the rat than atosiban (rat DR(10) = 0.44 mg/kg iv).,"2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16250654/),%,13-31,91940,DB00067,Vasopressin
,1738412,Uosm,"Higher PGE1 infusion rates (0.05 and 0.1 micrograms/min/kg) were associated with a progressive increase of FCurea (50%, p less than 0.001 and 91%, p less than 0.001, respectively), fractional clearance of water and salt output, inulin and PAH clearance and reduced Uosm from 1,005 (22 SEM; basal value) to 772 (38 SEM; minimum value) mosm/kg (p less than 0.001).",Inhibition of urea tubular reabsorption by PGE1 infusion in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738412/),[mosm] / [kg],"1,005",93491,DB00067,Vasopressin
,1738412,Uosm,"Higher PGE1 infusion rates (0.05 and 0.1 micrograms/min/kg) were associated with a progressive increase of FCurea (50%, p less than 0.001 and 91%, p less than 0.001, respectively), fractional clearance of water and salt output, inulin and PAH clearance and reduced Uosm from 1,005 (22 SEM; basal value) to 772 (38 SEM; minimum value) mosm/kg (p less than 0.001).",Inhibition of urea tubular reabsorption by PGE1 infusion in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1738412/),[mosm] / [kg],772,93492,DB00067,Vasopressin
below,10424322,urine flow rate,"In the dose titration study ascending doses of F992 were administered to volunteers in pairs in order to find a dose that within 1 h after the infusion, in both subjects, caused a reduction of the urine flow rate to below 5 ml x min(-1) (target dose).",Pharmacokinetics and antidiuretic effect of a new vasopressin analogue (F992) in overhydrated male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424322/),[ml] / [min],5,96541,DB00067,Vasopressin
,10424322,half-lives of elimination,"After infusion of 4.0 and 8.0 microg, the median half-lives of elimination were 4.72 (range 3.99-6.53) h and 3.85 (range 3.04-11.08) h, respectively.",Pharmacokinetics and antidiuretic effect of a new vasopressin analogue (F992) in overhydrated male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424322/),h,4.72,96542,DB00067,Vasopressin
,10424322,half-lives of elimination,"After infusion of 4.0 and 8.0 microg, the median half-lives of elimination were 4.72 (range 3.99-6.53) h and 3.85 (range 3.04-11.08) h, respectively.",Pharmacokinetics and antidiuretic effect of a new vasopressin analogue (F992) in overhydrated male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424322/),h,3.85,96543,DB00067,Vasopressin
,10424322,plasma clearance,The plasma clearance and the volume of distribution at steady state were estimated to be 0.88 (SD 0.24) ml x min(-1) x kg(-1) and 326 (SD 68) ml x kg(-1)] after infusion of 4 microg.,Pharmacokinetics and antidiuretic effect of a new vasopressin analogue (F992) in overhydrated male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424322/),[ml] / [kg·min],0.88,96544,DB00067,Vasopressin
,10424322,volume of distribution at steady state,The plasma clearance and the volume of distribution at steady state were estimated to be 0.88 (SD 0.24) ml x min(-1) x kg(-1) and 326 (SD 68) ml x kg(-1)] after infusion of 4 microg.,Pharmacokinetics and antidiuretic effect of a new vasopressin analogue (F992) in overhydrated male volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424322/),[ml] / [kg],326,96545,DB00067,Vasopressin
,10424322,maximum mean urine osmolalities,Significantly (P = 0.033) different maximum mean urine osmolalities were produced after infusion of 4.0 and 8.0 microg of F992 (534 (SD 318) vs 732 (SD 189) mOsmol x kg(-1)).,Pharmacokinetics and antidiuretic effect of a new vasopressin analogue (F992) in overhydrated male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424322/),[mosmol] / [kg],534,96546,DB00067,Vasopressin
,10424322,maximum mean urine osmolalities,Significantly (P = 0.033) different maximum mean urine osmolalities were produced after infusion of 4.0 and 8.0 microg of F992 (534 (SD 318) vs 732 (SD 189) mOsmol x kg(-1)).,Pharmacokinetics and antidiuretic effect of a new vasopressin analogue (F992) in overhydrated male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424322/),[mosmol] / [kg],732,96547,DB00067,Vasopressin
,14678081,maximal,"The plasma concentrations of SR 49059 appeared to be dose related, with mean maximal values of 62.0, 163.7 and 468.0 ng/ml in the 25, 75 and 200 mg dose groups, respectively, in Period 1 with vasopressin and 34.4, 116.7 and 418.0 ng/mL, respectively, in Period 2 with oxytocin.",Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14678081/),[ng] / [ml],62.0,99353,DB00067,Vasopressin
,14678081,maximal,"The plasma concentrations of SR 49059 appeared to be dose related, with mean maximal values of 62.0, 163.7 and 468.0 ng/ml in the 25, 75 and 200 mg dose groups, respectively, in Period 1 with vasopressin and 34.4, 116.7 and 418.0 ng/mL, respectively, in Period 2 with oxytocin.",Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14678081/),[ng] / [ml],163.7,99354,DB00067,Vasopressin
,14678081,maximal,"The plasma concentrations of SR 49059 appeared to be dose related, with mean maximal values of 62.0, 163.7 and 468.0 ng/ml in the 25, 75 and 200 mg dose groups, respectively, in Period 1 with vasopressin and 34.4, 116.7 and 418.0 ng/mL, respectively, in Period 2 with oxytocin.",Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14678081/),[ng] / [ml],468.0,99355,DB00067,Vasopressin
,14678081,maximal,"The plasma concentrations of SR 49059 appeared to be dose related, with mean maximal values of 62.0, 163.7 and 468.0 ng/ml in the 25, 75 and 200 mg dose groups, respectively, in Period 1 with vasopressin and 34.4, 116.7 and 418.0 ng/mL, respectively, in Period 2 with oxytocin.",Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14678081/),[ng] / [ml],34.4,99356,DB00067,Vasopressin
,14678081,maximal,"The plasma concentrations of SR 49059 appeared to be dose related, with mean maximal values of 62.0, 163.7 and 468.0 ng/ml in the 25, 75 and 200 mg dose groups, respectively, in Period 1 with vasopressin and 34.4, 116.7 and 418.0 ng/mL, respectively, in Period 2 with oxytocin.",Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14678081/),[ng] / [ml],116.7,99357,DB00067,Vasopressin
,14678081,maximal,"The plasma concentrations of SR 49059 appeared to be dose related, with mean maximal values of 62.0, 163.7 and 468.0 ng/ml in the 25, 75 and 200 mg dose groups, respectively, in Period 1 with vasopressin and 34.4, 116.7 and 418.0 ng/mL, respectively, in Period 2 with oxytocin.",Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14678081/),[ng] / [ml],418.0,99358,DB00067,Vasopressin
,14678081,Tmax,Tmax was observed at about 1 h.,Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14678081/),h,1,99359,DB00067,Vasopressin
,12911582,t(1/2),"The median t(1/2) VWF:Ag in the Type 1 VWD and mild hemophilia A groups were 4.6 h and 9.5 h, respectively.",Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12911582/),h,4.6,101205,DB00067,Vasopressin
,12911582,t(1/2),"The median t(1/2) VWF:Ag in the Type 1 VWD and mild hemophilia A groups were 4.6 h and 9.5 h, respectively.",Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12911582/),h,9.5,101206,DB00067,Vasopressin
,10070128,urinary excretion rate,The urinary excretion rate of albumin was elevated up to 15-fold (37 +/- 17 micrograms/min).,"Cardiovascular, endocrine, and renal effects of urodilatin in normal humans. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10070128/),[μg] / [min],37,101844,DB00067,Vasopressin
<,10070128,excretion rate,Use of a newly developed assay revealed that baseline urinary urodilatin excretion rate was low (<10 pg/min) and that fractional excretion of urodilatin remained below 0.1%.,"Cardiovascular, endocrine, and renal effects of urodilatin in normal humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10070128/),[pg] / [min],10,101845,DB00067,Vasopressin
below,10070128,fractional excretion,Use of a newly developed assay revealed that baseline urinary urodilatin excretion rate was low (<10 pg/min) and that fractional excretion of urodilatin remained below 0.1%.,"Cardiovascular, endocrine, and renal effects of urodilatin in normal humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10070128/),%,0.1,101846,DB00067,Vasopressin
,18612043,MCR,"MCR(AVP) was unchanged throughout the 1st mo (P > 0.2), averaging 205 +/- 17 ml.kg(-1).min(-1), and was associated with an elevated PR(AVP), 973 +/- 267 pg.kg(-1).min(-1), which also was unchanged (P > 0.1).",Metabolism and synthesis of arginine vasopressin in conscious newborn sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18612043/),[ml] / [kg·min],205,107181,DB00067,Vasopressin
,18612043,PR(AVP),"MCR(AVP) was unchanged throughout the 1st mo (P > 0.2), averaging 205 +/- 17 ml.kg(-1).min(-1), and was associated with an elevated PR(AVP), 973 +/- 267 pg.kg(-1).min(-1), which also was unchanged (P > 0.1).",Metabolism and synthesis of arginine vasopressin in conscious newborn sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18612043/),[pg] / [kg·min],973,107182,DB00067,Vasopressin
,3101710,bioavailability,The bioavailability of G-1-N in the rat and in the dog is practically 100%.,"[Hypotensive, antianginal action and pharmacokinetics of glyceryl-1-nitrate in rats and dogs]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3101710/),%,100,107989,DB00067,Vasopressin
,2521208,half-life (t1/2),"The elimination of VP after iv injection involved a rapid initial phase and a slow late component, with corresponding half-life (t1/2) values of 0.9 and 5.4 min, respectively.",Pharmacokinetics of vasopressin and atrial natriuretic peptide in anesthetized rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521208/),min,0.9,108990,DB00067,Vasopressin
,2521208,half-life (t1/2),"The elimination of VP after iv injection involved a rapid initial phase and a slow late component, with corresponding half-life (t1/2) values of 0.9 and 5.4 min, respectively.",Pharmacokinetics of vasopressin and atrial natriuretic peptide in anesthetized rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521208/),min,5.4,108991,DB00067,Vasopressin
,2521208,t1/2,"When carotid sinus pressure was increased to 160 mm Hg to inhibit VP release, the t1/2 of VP was 1.3 min.",Pharmacokinetics of vasopressin and atrial natriuretic peptide in anesthetized rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521208/),min,1.3,108992,DB00067,Vasopressin
,2521208,t1/2,The t1/2 of immunoreactive (IR) ANP after iv infusion was 1.2 min.,Pharmacokinetics of vasopressin and atrial natriuretic peptide in anesthetized rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521208/),min,1.2,108993,DB00067,Vasopressin
,2521208,t1/2,The t1/2 of IR-ANP after elevation of carotid sinus pressure to 160 mm Hg was 3.2 min.,Pharmacokinetics of vasopressin and atrial natriuretic peptide in anesthetized rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521208/),min,3.2,108994,DB00067,Vasopressin
,15373927,systemic clearance,"The mean systemic clearance of desmopressin was 10 litres h(-1) in healthy subjects and 2.9 litres h(-1) in patients with severe renal impairment (difference -7.5 litres h(-1), 95% CI [-11; -4.3] litres h(-1)).",Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373927/),[l] / [h],10,110546,DB00067,Vasopressin
,15373927,systemic clearance,"The mean systemic clearance of desmopressin was 10 litres h(-1) in healthy subjects and 2.9 litres h(-1) in patients with severe renal impairment (difference -7.5 litres h(-1), 95% CI [-11; -4.3] litres h(-1)).",Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373927/),[l] / [h],2.9,110547,DB00067,Vasopressin
,15373927,terminal half-life,"Correspondingly, the mean terminal half-life, was 3.7 h in healthy subjects and 10 h in patients with severe renal impairment (difference 6.7 h, 95% CI [4.0; 9.4] h).",Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373927/),h,3.7,110548,DB00067,Vasopressin
,15373927,terminal half-life,"Correspondingly, the mean terminal half-life, was 3.7 h in healthy subjects and 10 h in patients with severe renal impairment (difference 6.7 h, 95% CI [4.0; 9.4] h).",Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15373927/),h,10,110549,DB00067,Vasopressin
,3751461,total body clearance,"When given intravenously as bolus injection (10 nmol/kg/body weight), the total body clearance amounted to 0.623 +/- 0.099 (SEM) l/h kg and the half-life to 16.2 +/- 2.4 min.",Pharmacokinetics in the human of a new synthetic vasopressin and oxytocin uterine antagonist. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3751461/),[l] / [h·kg],0.623,114500,DB00067,Vasopressin
,3751461,half-life,"When given intravenously as bolus injection (10 nmol/kg/body weight), the total body clearance amounted to 0.623 +/- 0.099 (SEM) l/h kg and the half-life to 16.2 +/- 2.4 min.",Pharmacokinetics in the human of a new synthetic vasopressin and oxytocin uterine antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3751461/),min,16.2,114501,DB00067,Vasopressin
,3751461,bioavailability,"After intranasal administration (100 nmol/kg/body weight), the bioavailability was 10.5 +/- 2.9%.",Pharmacokinetics in the human of a new synthetic vasopressin and oxytocin uterine antagonist. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3751461/),%,10.5,114502,DB00067,Vasopressin
,12869367,Metabolic clearance rates,"Metabolic clearance rates were higher for ANG III and ANG IV (391 +/- 19 and 274 +/- 13 ml.kg-1.min-1, respectively) than for ANG II (107 +/- 13 ml.kg-1.min-1).","Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12869367/),[ml] / [kg·min],391,114797,DB00067,Vasopressin
,12869367,Metabolic clearance rates,"Metabolic clearance rates were higher for ANG III and ANG IV (391 +/- 19 and 274 +/- 13 ml.kg-1.min-1, respectively) than for ANG II (107 +/- 13 ml.kg-1.min-1).","Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12869367/),[ml] / [kg·min],274,114798,DB00067,Vasopressin
,12869367,Metabolic clearance rates,"Metabolic clearance rates were higher for ANG III and ANG IV (391 +/- 19 and 274 +/- 13 ml.kg-1.min-1, respectively) than for ANG II (107 +/- 13 ml.kg-1.min-1).","Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12869367/),[ml] / [kg·min],107,114799,DB00067,Vasopressin
,12869367,sodium excretion,"ANG II increased ANG IR by 60 +/- 7 pmol/ml, blood pressure by 30%, increased plasma aldosterone markedly (to 345 +/- 72 pg/ml), and plasma vasopressin transiently, while reducing glomerular filtration rate (40 +/- 2 to 33 +/- 2 ml/min), sodium excretion (50 +/- 7 to 16 +/- 4 micromol/min), and urine flow.","Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12869367/),,50,114800,DB00067,Vasopressin
,12869367,sodium excretion,"ANG II increased ANG IR by 60 +/- 7 pmol/ml, blood pressure by 30%, increased plasma aldosterone markedly (to 345 +/- 72 pg/ml), and plasma vasopressin transiently, while reducing glomerular filtration rate (40 +/- 2 to 33 +/- 2 ml/min), sodium excretion (50 +/- 7 to 16 +/- 4 micromol/min), and urine flow.","Effects of different angiotensins during acute, double blockade of the renin system in conscious dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12869367/),,16,114801,DB00067,Vasopressin
,12753429,plasma clearance,"The age was 58 (20-76) years (median and range), serum creatinine 447 (309-691) micromol/l and plasma clearance of iohexol 16 (8-19) ml/min./1.73 m2 body surface.",Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12753429/),[ml] / [·1.73·m2·min],16,116952,DB00067,Vasopressin
,12753429,total clearance,"The total clearance of desmopressin was 0.35 (0.21-0.47) ml/min./kg, the volume of distribution at steady state was 0.30 (0.17-0.38) l/kg and the terminal half-life 9.7 (8.4-16) hr.",Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12753429/),[ml] / [·kg·min],0.35,116953,DB00067,Vasopressin
,12753429,volume of distribution at steady state,"The total clearance of desmopressin was 0.35 (0.21-0.47) ml/min./kg, the volume of distribution at steady state was 0.30 (0.17-0.38) l/kg and the terminal half-life 9.7 (8.4-16) hr.",Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12753429/),[l] / [kg],0.30,116954,DB00067,Vasopressin
,12753429,terminal half-life,"The total clearance of desmopressin was 0.35 (0.21-0.47) ml/min./kg, the volume of distribution at steady state was 0.30 (0.17-0.38) l/kg and the terminal half-life 9.7 (8.4-16) hr.",Pharmacokinetics and antidiuretic effect of high-dose desmopressin in patients with chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12753429/),h,9.7,116955,DB00067,Vasopressin
,9816174,peritoneal fluid:plasma AUC ratio,"The pharmacokinetics of 5-fluorouracil were not altered by vasopressin; however, vasopressin increased the peritoneal fluid:plasma AUC ratio for CBDCA from 30.6 +/- 5.6 to 70. 6 +/- 7.4 (P < 0.01) and increased the lymph:plasma AUC ratio from 1.1 +/- 0.4 to 2.6 +/- 0.22 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,30.6,120412,DB00067,Vasopressin
,9816174,peritoneal fluid:plasma AUC ratio,"The pharmacokinetics of 5-fluorouracil were not altered by vasopressin; however, vasopressin increased the peritoneal fluid:plasma AUC ratio for CBDCA from 30.6 +/- 5.6 to 70. 6 +/- 7.4 (P < 0.01) and increased the lymph:plasma AUC ratio from 1.1 +/- 0.4 to 2.6 +/- 0.22 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,70. 6,120413,DB00067,Vasopressin
,9816174,lymph:plasma AUC ratio,"The pharmacokinetics of 5-fluorouracil were not altered by vasopressin; however, vasopressin increased the peritoneal fluid:plasma AUC ratio for CBDCA from 30.6 +/- 5.6 to 70. 6 +/- 7.4 (P < 0.01) and increased the lymph:plasma AUC ratio from 1.1 +/- 0.4 to 2.6 +/- 0.22 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,1.1,120414,DB00067,Vasopressin
,9816174,lymph:plasma AUC ratio,"The pharmacokinetics of 5-fluorouracil were not altered by vasopressin; however, vasopressin increased the peritoneal fluid:plasma AUC ratio for CBDCA from 30.6 +/- 5.6 to 70. 6 +/- 7.4 (P < 0.01) and increased the lymph:plasma AUC ratio from 1.1 +/- 0.4 to 2.6 +/- 0.22 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,2.6,120415,DB00067,Vasopressin
,9816174,peritoneal fluid:plasma AUC ratio,"In the case of VP-16, vasopressin increased the peritoneal fluid:plasma AUC ratio from 129 +/- 35 to 350 +/- 76 (P < 0.05) and the lymph:plasma AUC ratio from 2.1 +/- 0.6 to 10.6 +/- 3.5 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,129,120416,DB00067,Vasopressin
,9816174,peritoneal fluid:plasma AUC ratio,"In the case of VP-16, vasopressin increased the peritoneal fluid:plasma AUC ratio from 129 +/- 35 to 350 +/- 76 (P < 0.05) and the lymph:plasma AUC ratio from 2.1 +/- 0.6 to 10.6 +/- 3.5 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,350,120417,DB00067,Vasopressin
,9816174,lymph:plasma AUC ratio,"In the case of VP-16, vasopressin increased the peritoneal fluid:plasma AUC ratio from 129 +/- 35 to 350 +/- 76 (P < 0.05) and the lymph:plasma AUC ratio from 2.1 +/- 0.6 to 10.6 +/- 3.5 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,2.1,120418,DB00067,Vasopressin
,9816174,lymph:plasma AUC ratio,"In the case of VP-16, vasopressin increased the peritoneal fluid:plasma AUC ratio from 129 +/- 35 to 350 +/- 76 (P < 0.05) and the lymph:plasma AUC ratio from 2.1 +/- 0.6 to 10.6 +/- 3.5 (P < 0.05).","Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816174/),,10.6,120419,DB00067,Vasopressin
,9443610,IC50,"Oryzalin inhibited vasopressin, bradykinin and platelet-derived growth factor [Ca2+]i signalling in Swiss 3T3 fibroblasts with IC50 values of 14, 16 and 18 microM, respectively.","Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443610/),μM,14,121835,DB00067,Vasopressin
,9443610,IC50,"Oryzalin inhibited vasopressin, bradykinin and platelet-derived growth factor [Ca2+]i signalling in Swiss 3T3 fibroblasts with IC50 values of 14, 16 and 18 microM, respectively.","Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443610/),μM,16,121836,DB00067,Vasopressin
,9443610,IC50,"Oryzalin inhibited vasopressin, bradykinin and platelet-derived growth factor [Ca2+]i signalling in Swiss 3T3 fibroblasts with IC50 values of 14, 16 and 18 microM, respectively.","Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443610/),μM,18,121837,DB00067,Vasopressin
,9443610,IC50,45Ca2+ uptake into nonmitochondrial stores of saponin-permeabilized Swiss 3T3 cells was inhibited by oryzalin with an IC50 of 34 microM.,"Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443610/),μM,34,121838,DB00067,Vasopressin
,9443610,IC50,Oryzalin inhibited colony formation of HT-29 colon carcinoma cells with an IC50 of 8 microM and inhibited the growth of a number of other cancer cell lines and primary human tumors in vitro with IC50 values in the range 3 to 22 microM.,"Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443610/),μM,8,121839,DB00067,Vasopressin
,9443610,IC50,Oryzalin inhibited colony formation of HT-29 colon carcinoma cells with an IC50 of 8 microM and inhibited the growth of a number of other cancer cell lines and primary human tumors in vitro with IC50 values in the range 3 to 22 microM.,"Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443610/),μM,3 to 22,121840,DB00067,Vasopressin
,9443610,peak plasma concentration,The peak plasma concentration of oryzalin following repeated subcutaneous administration of oryzalin at 600 mg/kg per day to mice was 37 microM and of its major metabolite N-depropyl oryzalin was 53 microM.,"Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443610/),μM,37,121841,DB00067,Vasopressin
,9443610,peak plasma concentration,The peak plasma concentration of oryzalin following repeated subcutaneous administration of oryzalin at 600 mg/kg per day to mice was 37 microM and of its major metabolite N-depropyl oryzalin was 53 microM.,"Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9443610/),μM,53,121842,DB00067,Vasopressin
,10470765,plasma concentrations,"At both 90 secs and 5 mins after drug administration, intravenous and intraosseous administration of vasopressin resulted in comparable mean (+/-SEM) coronary perfusion pressure (43+/-4 vs. 44+/-3 and 30+/-2 vs. 37+/-2 mm Hg, respectively) and vasopressin plasma concentrations (13,706+/-1,857 vs. 16,166+/-3,114 pg/mL and 10,372+/-883 vs. 8246+/-2211 pg/mL, respectively).",Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),[pg] / [ml],"13,",130386,DB00067,Vasopressin
,10470765,plasma concentrations,"At both 90 secs and 5 mins after drug administration, intravenous and intraosseous administration of vasopressin resulted in comparable mean (+/-SEM) coronary perfusion pressure (43+/-4 vs. 44+/-3 and 30+/-2 vs. 37+/-2 mm Hg, respectively) and vasopressin plasma concentrations (13,706+/-1,857 vs. 16,166+/-3,114 pg/mL and 10,372+/-883 vs. 8246+/-2211 pg/mL, respectively).",Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),[pg] / [ml],"16,166",130387,DB00067,Vasopressin
,10470765,plasma concentrations,"At both 90 secs and 5 mins after drug administration, intravenous and intraosseous administration of vasopressin resulted in comparable mean (+/-SEM) coronary perfusion pressure (43+/-4 vs. 44+/-3 and 30+/-2 vs. 37+/-2 mm Hg, respectively) and vasopressin plasma concentrations (13,706+/-1,857 vs. 16,166+/-3,114 pg/mL and 10,372+/-883 vs. 8246+/-2211 pg/mL, respectively).",Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),[pg] / [ml],"10,372",130388,DB00067,Vasopressin
,10470765,plasma concentrations,"At both 90 secs and 5 mins after drug administration, intravenous and intraosseous administration of vasopressin resulted in comparable mean (+/-SEM) coronary perfusion pressure (43+/-4 vs. 44+/-3 and 30+/-2 vs. 37+/-2 mm Hg, respectively) and vasopressin plasma concentrations (13,706+/-1,857 vs. 16,166+/-3,114 pg/mL and 10,372+/-883 vs. 8246+/-2211 pg/mL, respectively).",Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),[pg] / [ml],8246,130389,DB00067,Vasopressin
,10470765,arterial,All animals in both groups were successfully resuscitated; pigs that received intraosseous vasopressin had a significantly higher (p < .05) mean arterial (92+/-6 vs. 129+/-12 mm Hg) and coronary perfusion pressure (84+/-11 vs. 119+/-11 mm Hg) at 5 mins of return of spontaneous circulation.,Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),mm,92,130390,DB00067,Vasopressin
,10470765,arterial,All animals in both groups were successfully resuscitated; pigs that received intraosseous vasopressin had a significantly higher (p < .05) mean arterial (92+/-6 vs. 129+/-12 mm Hg) and coronary perfusion pressure (84+/-11 vs. 119+/-11 mm Hg) at 5 mins of return of spontaneous circulation.,Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),mm,129,130391,DB00067,Vasopressin
,10470765,coronary perfusion pressure,All animals in both groups were successfully resuscitated; pigs that received intraosseous vasopressin had a significantly higher (p < .05) mean arterial (92+/-6 vs. 129+/-12 mm Hg) and coronary perfusion pressure (84+/-11 vs. 119+/-11 mm Hg) at 5 mins of return of spontaneous circulation.,Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),hg·mm,84,130392,DB00067,Vasopressin
,10470765,coronary perfusion pressure,All animals in both groups were successfully resuscitated; pigs that received intraosseous vasopressin had a significantly higher (p < .05) mean arterial (92+/-6 vs. 129+/-12 mm Hg) and coronary perfusion pressure (84+/-11 vs. 119+/-11 mm Hg) at 5 mins of return of spontaneous circulation.,Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),hg·mm,119,130393,DB00067,Vasopressin
,8479003,Oral bioavailability,Oral bioavailability in the fistulated sheep was only 5.5 +/- 1.8% (mean +/- SE).,"Plasma ronidazole concentrations in sheep after intravenous, oral, intraruminal and intraabomasal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8479003/),%,5.5,133914,DB00067,Vasopressin
,8479003,bioavailability,"After administration of the same dose directly in the abomasum through the intraabomasal fistula, bioavailability was increased to 86.0 +/- 8.9%.","Plasma ronidazole concentrations in sheep after intravenous, oral, intraruminal and intraabomasal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8479003/),%,86.0,133915,DB00067,Vasopressin
,8479003,oral biodisponibility,"In the non-fistulated sheep, oral biodisponibility was 2.6 +/- 0.5%.","Plasma ronidazole concentrations in sheep after intravenous, oral, intraruminal and intraabomasal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8479003/),%,2.6,133916,DB00067,Vasopressin
,8479003,bioavailability,"After water was restricted for 48 h before the oral ronidazole administration to these sheep, bioavailability was slightly increased (6.0 +/- 3.1%).","Plasma ronidazole concentrations in sheep after intravenous, oral, intraruminal and intraabomasal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8479003/),%,6.0,133917,DB00067,Vasopressin
,8479003,bioavailability,"When desmopressin acetate was injected i.v. before the oral ronidazole administration, bioavailability was 10.6 +/- 6.5%.","Plasma ronidazole concentrations in sheep after intravenous, oral, intraruminal and intraabomasal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8479003/),%,10.6,133918,DB00067,Vasopressin
,8479003,oral bioavailability,"When glypressin, another vasopressin analogue, was used, oral bioavailability was not influenced: 2.4 +/- 1.3%.","Plasma ronidazole concentrations in sheep after intravenous, oral, intraruminal and intraabomasal administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8479003/),%,2.4,133919,DB00067,Vasopressin
,8479003,first order rate constant,Ronidazole was also incubated with ruminal contents and the ronidazole concentration decreased with a first order rate constant of 0.122 +/- 0.050 min-1 (mean +/- SE).,"Plasma ronidazole concentrations in sheep after intravenous, oral, intraruminal and intraabomasal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8479003/),1/[min],0.122,133920,DB00067,Vasopressin
,1335395,steady-state concentrations,"3. In normal subjects, the metabolic clearance rate was determined at two infusion rates producing steady-state concentrations of arginine vasopressin of 1.3 and 4.4 pmol/l.",Metabolic clearance rate of arginine vasopressin in severe chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1335395/),[pM] / [l],1.3,133963,DB00067,Vasopressin
,1335395,steady-state concentrations,"3. In normal subjects, the metabolic clearance rate was determined at two infusion rates producing steady-state concentrations of arginine vasopressin of 1.3 and 4.4 pmol/l.",Metabolic clearance rate of arginine vasopressin in severe chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1335395/),[pM] / [l],4.4,133964,DB00067,Vasopressin
,1335395,steady-state concentration,"In the patients with renal failure, a single infusion rate was used, producing a steady-state concentration of 1.5 pmol/l. 4.",Metabolic clearance rate of arginine vasopressin in severe chronic renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1335395/),[pM] / [l],1.5,133965,DB00067,Vasopressin
,1335395,metabolic clearance rate,"At comparable plasma arginine vasopressin concentrations, metabolic clearance rate was significantly reduced in patients with renal failure (normal 1168 +/- 235 ml/min versus renal failure 584 +/- 169 ml/min; means +/- SD; P < 0.001).",Metabolic clearance rate of arginine vasopressin in severe chronic renal failure. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1335395/),[ml] / [min],1168,133966,DB00067,Vasopressin
,1335395,metabolic clearance rate,"At comparable plasma arginine vasopressin concentrations, metabolic clearance rate was significantly reduced in patients with renal failure (normal 1168 +/- 235 ml/min versus renal failure 584 +/- 169 ml/min; means +/- SD; P < 0.001).",Metabolic clearance rate of arginine vasopressin in severe chronic renal failure. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1335395/),[ml] / [min],584,133967,DB00067,Vasopressin
,1335395,Free water clearance,"5. Free water clearance was significantly reduced in normal subjects during the arginine vasopressin infusion from 8.19 +/- 2.61 to -1.41 +/- 0.51 ml/min (P < 0.001), but was unchanged in the patients with renal failure after attaining comparable plasma arginine vasopressin concentrations.",Metabolic clearance rate of arginine vasopressin in severe chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1335395/),[ml] / [min],8.19,133968,DB00067,Vasopressin
,1335395,Free water clearance,"5. Free water clearance was significantly reduced in normal subjects during the arginine vasopressin infusion from 8.19 +/- 2.61 to -1.41 +/- 0.51 ml/min (P < 0.001), but was unchanged in the patients with renal failure after attaining comparable plasma arginine vasopressin concentrations.",Metabolic clearance rate of arginine vasopressin in severe chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1335395/),[ml] / [min],-,133969,DB00067,Vasopressin
,1335395,Free water clearance,"5. Free water clearance was significantly reduced in normal subjects during the arginine vasopressin infusion from 8.19 +/- 2.61 to -1.41 +/- 0.51 ml/min (P < 0.001), but was unchanged in the patients with renal failure after attaining comparable plasma arginine vasopressin concentrations.",Metabolic clearance rate of arginine vasopressin in severe chronic renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1335395/),[ml] / [min],1.41,133970,DB00067,Vasopressin
,1335395,metabolic clearance rate,6. In normal subjects there was a small but significant fall in metabolic clearance rate at the higher steady-state arginine vasopressin concentration (1168 +/- 235 ml/min at 1.3 pmol/l versus 1059 +/- 269 ml/min at 4.4 pmol/l; P = 0.016).,Metabolic clearance rate of arginine vasopressin in severe chronic renal failure. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1335395/),[ml] / [min],1168,133971,DB00067,Vasopressin
,1335395,metabolic clearance rate,6. In normal subjects there was a small but significant fall in metabolic clearance rate at the higher steady-state arginine vasopressin concentration (1168 +/- 235 ml/min at 1.3 pmol/l versus 1059 +/- 269 ml/min at 4.4 pmol/l; P = 0.016).,Metabolic clearance rate of arginine vasopressin in severe chronic renal failure. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1335395/),[ml] / [min],1059,133972,DB00067,Vasopressin
,28270248,time to ROSC,"Analysis of Variance (ANOVA) indicated the mean time to ROSC for HIO and IV was 621.20 seconds (SD=204.21 seconds) and 554.50 seconds (SD=213.96 seconds), respectively, with no significant difference between the groups (U=11; P=.22).",The Resuscitative and Pharmacokinetic Effects of Humeral Intraosseous Vasopressin in a Swine Model of Ventricular Fibrillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270248/),seconds,621.20,135705,DB00067,Vasopressin
,28270248,time to ROSC,"Analysis of Variance (ANOVA) indicated the mean time to ROSC for HIO and IV was 621.20 seconds (SD=204.21 seconds) and 554.50 seconds (SD=213.96 seconds), respectively, with no significant difference between the groups (U=11; P=.22).",The Resuscitative and Pharmacokinetic Effects of Humeral Intraosseous Vasopressin in a Swine Model of Ventricular Fibrillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270248/),seconds,554.50,135706,DB00067,Vasopressin
,28270248,maximum plasma concentration (Cmax),"Multivariate Analysis of Variance (MANOVA) revealed the maximum plasma concentration (Cmax) and time to maximum concentration (Tmax) of vasopressin in the HIO and IV groups was 71753.9 pg/mL (SD=26744.58 pg/mL) and 61853.7 pg/mL (SD=22745.04 pg/mL); 111.42 seconds (SD=51.3 seconds) and 114.55 seconds (SD=55.02 seconds), respectively.",The Resuscitative and Pharmacokinetic Effects of Humeral Intraosseous Vasopressin in a Swine Model of Ventricular Fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270248/),[pg] / [ml],71753.9,135707,DB00067,Vasopressin
,28270248,time to maximum concentration (Tmax),"Multivariate Analysis of Variance (MANOVA) revealed the maximum plasma concentration (Cmax) and time to maximum concentration (Tmax) of vasopressin in the HIO and IV groups was 71753.9 pg/mL (SD=26744.58 pg/mL) and 61853.7 pg/mL (SD=22745.04 pg/mL); 111.42 seconds (SD=51.3 seconds) and 114.55 seconds (SD=55.02 seconds), respectively.",The Resuscitative and Pharmacokinetic Effects of Humeral Intraosseous Vasopressin in a Swine Model of Ventricular Fibrillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270248/),[pg] / [ml],61853.7,135708,DB00067,Vasopressin
,28270248,time to maximum concentration (Tmax),"Multivariate Analysis of Variance (MANOVA) revealed the maximum plasma concentration (Cmax) and time to maximum concentration (Tmax) of vasopressin in the HIO and IV groups was 71753.9 pg/mL (SD=26744.58 pg/mL) and 61853.7 pg/mL (SD=22745.04 pg/mL); 111.42 seconds (SD=51.3 seconds) and 114.55 seconds (SD=55.02 seconds), respectively.",The Resuscitative and Pharmacokinetic Effects of Humeral Intraosseous Vasopressin in a Swine Model of Ventricular Fibrillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270248/),seconds,111.42,135709,DB00067,Vasopressin
,28270248,time to maximum concentration (Tmax),"Multivariate Analysis of Variance (MANOVA) revealed the maximum plasma concentration (Cmax) and time to maximum concentration (Tmax) of vasopressin in the HIO and IV groups was 71753.9 pg/mL (SD=26744.58 pg/mL) and 61853.7 pg/mL (SD=22745.04 pg/mL); 111.42 seconds (SD=51.3 seconds) and 114.55 seconds (SD=55.02 seconds), respectively.",The Resuscitative and Pharmacokinetic Effects of Humeral Intraosseous Vasopressin in a Swine Model of Ventricular Fibrillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270248/),seconds,114.55,135710,DB00067,Vasopressin
,20300802,"absorption half-lives, t (1/2a)","The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),min,23.7,137251,DB00067,Vasopressin
,20300802,"absorption half-lives, t (1/2a)","The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),min,28.9,137252,DB00067,Vasopressin
,20300802,"absorption half-lives, t (1/2a)","The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),min,14.4,137253,DB00067,Vasopressin
,20300802,"absorption half-lives, t (1/2a)","The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),min,14.1,137254,DB00067,Vasopressin
,20300802,bioavailability,"The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),%,72.8,137255,DB00067,Vasopressin
,20300802,bioavailability,"The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),%,89.9,137256,DB00067,Vasopressin
,20300802,bioavailability,"The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),%,90.0,137257,DB00067,Vasopressin
,20300802,bioavailability,"The absorption half-lives, t (1/2a), of rhGH and DDAVP from dissolving microneedles were 23.7 ± 4.3-28.9 ± 5.2 and 14.4 ± 2.9-14.1 ± 1.1 min; the extents of bioavailability were 72.8 ± 4.2-89.9 ± 10.0% and 90.0 ± 15.4-93.1 ± 10.3%, respectively.",Two-layered dissolving microneedles for percutaneous delivery of peptide/protein drugs in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20300802/),%,93.1,137258,DB00067,Vasopressin
,32746466,activity,"Median age was 28 years (range: 5-76), median predose VWF activity was 0.37 IU/mL (range: 0.06-1.13), and median VWF activity response at peak level was 0.64 IU/mL (range: 0.04-4.04).",Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32746466/),[iu] / [ml],0.37,139444,DB00067,Vasopressin
,32746466,activity response at peak level,"Median age was 28 years (range: 5-76), median predose VWF activity was 0.37 IU/mL (range: 0.06-1.13), and median VWF activity response at peak level was 0.64 IU/mL (range: 0.04-4.04).",Population Pharmacokinetic Modeling of von Willebrand Factor Activity in von Willebrand Disease Patients after Desmopressin Administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32746466/),[iu] / [ml],0.64,139445,DB00067,Vasopressin
,1442135,Clearance,"Clearance of creatinine and excretion of urea decreased (39 +/- 4 to 29 +/- 3 ml min-1 and 87 +/- 16 to 71 +/- 14 mumol min-1, respectively).","Effects, release and disposal of endothelin-1 in conscious dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442135/),[ml] / [min],39,139950,DB00067,Vasopressin
,1442135,excretion,"Clearance of creatinine and excretion of urea decreased (39 +/- 4 to 29 +/- 3 ml min-1 and 87 +/- 16 to 71 +/- 14 mumol min-1, respectively).","Effects, release and disposal of endothelin-1 in conscious dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442135/),[ml] / [min],29,139951,DB00067,Vasopressin
,1442135,excretion,"Clearance of creatinine and excretion of urea decreased (39 +/- 4 to 29 +/- 3 ml min-1 and 87 +/- 16 to 71 +/- 14 mumol min-1, respectively).","Effects, release and disposal of endothelin-1 in conscious dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442135/),[μM] / [min],87,139952,DB00067,Vasopressin
,1442135,excretion,"Clearance of creatinine and excretion of urea decreased (39 +/- 4 to 29 +/- 3 ml min-1 and 87 +/- 16 to 71 +/- 14 mumol min-1, respectively).","Effects, release and disposal of endothelin-1 in conscious dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442135/),[μM] / [min],71,139953,DB00067,Vasopressin
,1442135,initial t1/2,"Decay curves for ET-1 in venous and arterial plasma were identical, and initial t1/2 was 1.1 +/- 0.1 min.","Effects, release and disposal of endothelin-1 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1442135/),min,1.1,139954,DB00067,Vasopressin
,30873482,MRT,"The MRT of FVIII concentrate increased in all patients (mean from 17.6 h to 19.9 h, p < 0.001, 95% CI for MRT change: +4.7 to -0.3 h).",Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30873482/),h,17.6,143774,DB00067,Vasopressin
,30873482,MRT,"The MRT of FVIII concentrate increased in all patients (mean from 17.6 h to 19.9 h, p < 0.001, 95% CI for MRT change: +4.7 to -0.3 h).",Administration of DDAVP did not improve the pharmacokinetics of FVIII concentrate in a clinically significant manner. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30873482/),h,19.9,143775,DB00067,Vasopressin
,1320543,fractional lithium excretion,"Control levels of fractional lithium excretion (12.4 +/- 1.2%, mean +/- SEM) were not influenced by hydration, hydration plus arginine vasopressin administration or the lithium dosage.","Lithium clearance in dogs: effects of water loading, amiloride and lithium dosage. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320543/),%,12.4,143914,DB00067,Vasopressin
,1320543,fractional,"The low fractional lithium excretion even during amiloride infusion (14.1-16.8%) may well be due to a high fractional reabsorption of lithium in the proximal tubules; however, a significant reabsorption of lithium distal to the proximal straight tubules by amiloride-insensitive pathways cannot be excluded.","Lithium clearance in dogs: effects of water loading, amiloride and lithium dosage. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1320543/),%,14.1-16.8,143915,DB00067,Vasopressin
,3420013,Extraction recovery,Extraction recovery was 73 +/- 14% (mean +/- S.D.; n = 11) and good linearity was achieved in the concentration range of 0.25-128 pg/tube.,Radioimmunoassay of desglycinamide-arginine vasopressin and its application in a pharmacokinetic study in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3420013/),%,73,144231,DB00067,Vasopressin
,3420013,detection limit,"Instantaneous tracer addition resulted in a detection limit of 250 fg/tube, whereas 24 hours preincubation and delayed tracer addition resulted in a detection limit of 100 fg/tube.",Radioimmunoassay of desglycinamide-arginine vasopressin and its application in a pharmacokinetic study in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3420013/),f,100,144232,DB00067,Vasopressin
,3420013,t1/2,DGAVP plasma concentration showed a rapid distribution phase (t1/2 = 1.0 +/- 0.2 min) and a somewhat slower elimination phase (t1/2 = 7.2 +/- 2.1 min).,Radioimmunoassay of desglycinamide-arginine vasopressin and its application in a pharmacokinetic study in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3420013/),min,1.0,144233,DB00067,Vasopressin
,3420013,t1/2,DGAVP plasma concentration showed a rapid distribution phase (t1/2 = 1.0 +/- 0.2 min) and a somewhat slower elimination phase (t1/2 = 7.2 +/- 2.1 min).,Radioimmunoassay of desglycinamide-arginine vasopressin and its application in a pharmacokinetic study in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3420013/),min,7.2,144234,DB00067,Vasopressin
,3420013,CLss,High clearance values (CLss = 97 +/- 30 ml.min-1) suggest rapid metabolism by amino- and carboxy-peptidases.,Radioimmunoassay of desglycinamide-arginine vasopressin and its application in a pharmacokinetic study in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3420013/),[ml] / [min],97,144235,DB00067,Vasopressin
lower,2587414,half-life,The nonapeptide [Arg8]vasopressin was rapidly degraded with a half-life of lower than 1 minute after local administration into the hippocampus.,In vivo conversion of vasopressin after microinjection into limbic brain areas of rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2587414/),min,1,146917,DB00067,Vasopressin
,30504136,Total recovery,"Total recovery (mean ± S.D. percentage of dose; PCK vs. WT) of tolvaptan and two metabolites, DM-4103 and DM-4107, quantified by liquid chromatography-tandem mass spectroscopy, was 58.14% ± 24.72% vs. 43.40% ± 18.11% in liver, 20.10% ± 9.15% vs. 21.17% ± 12.51% in outflow perfusate, and 0.08% ± 0.01% vs. 0.39% ± 0.32% in bile.",Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30504136/),%,58.14,151672,DB00067,Vasopressin
,30504136,Total recovery,"Total recovery (mean ± S.D. percentage of dose; PCK vs. WT) of tolvaptan and two metabolites, DM-4103 and DM-4107, quantified by liquid chromatography-tandem mass spectroscopy, was 58.14% ± 24.72% vs. 43.40% ± 18.11% in liver, 20.10% ± 9.15% vs. 21.17% ± 12.51% in outflow perfusate, and 0.08% ± 0.01% vs. 0.39% ± 0.32% in bile.",Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30504136/),%,43.40,151673,DB00067,Vasopressin
,30504136,Total recovery,"Total recovery (mean ± S.D. percentage of dose; PCK vs. WT) of tolvaptan and two metabolites, DM-4103 and DM-4107, quantified by liquid chromatography-tandem mass spectroscopy, was 58.14% ± 24.72% vs. 43.40% ± 18.11% in liver, 20.10% ± 9.15% vs. 21.17% ± 12.51% in outflow perfusate, and 0.08% ± 0.01% vs. 0.39% ± 0.32% in bile.",Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30504136/),%,20.10,151674,DB00067,Vasopressin
,30504136,Total recovery,"Total recovery (mean ± S.D. percentage of dose; PCK vs. WT) of tolvaptan and two metabolites, DM-4103 and DM-4107, quantified by liquid chromatography-tandem mass spectroscopy, was 58.14% ± 24.72% vs. 43.40% ± 18.11% in liver, 20.10% ± 9.15% vs. 21.17% ± 12.51% in outflow perfusate, and 0.08% ± 0.01% vs. 0.39% ± 0.32% in bile.",Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30504136/),%,21.17,151675,DB00067,Vasopressin
,30504136,Total recovery,"Total recovery (mean ± S.D. percentage of dose; PCK vs. WT) of tolvaptan and two metabolites, DM-4103 and DM-4107, quantified by liquid chromatography-tandem mass spectroscopy, was 58.14% ± 24.72% vs. 43.40% ± 18.11% in liver, 20.10% ± 9.15% vs. 21.17% ± 12.51% in outflow perfusate, and 0.08% ± 0.01% vs. 0.39% ± 0.32% in bile.",Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30504136/),%,0.08,151676,DB00067,Vasopressin
,30504136,Total recovery,"Total recovery (mean ± S.D. percentage of dose; PCK vs. WT) of tolvaptan and two metabolites, DM-4103 and DM-4107, quantified by liquid chromatography-tandem mass spectroscopy, was 58.14% ± 24.72% vs. 43.40% ± 18.11% in liver, 20.10% ± 9.15% vs. 21.17% ± 12.51% in outflow perfusate, and 0.08% ± 0.01% vs. 0.39% ± 0.32% in bile.",Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30504136/),%,0.39,151677,DB00067,Vasopressin
,17234419,IC50,"The azetidinone LY307174 (1) was identified as a screening lead for the vasopressin V1a receptor (IC50 45 nM at the human V1a receptor) based on molecular similarity to ketoconazole (2), a known antagonist of the luteinizing hormone releasing hormone receptor.",Azetidinones as vasopressin V1a antagonists. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17234419/),nM,45,156010,DB00067,Vasopressin
<,17234419,Ki,"Structure-activity relationships for the series were explored to optimize receptor affinity and pharmacokinetic properties, resulting in compounds with Ki values <1nM and brain levels after oral dosing approximately 100-fold higher than receptor affinities.",Azetidinones as vasopressin V1a antagonists. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17234419/),nM,1,156011,DB00067,Vasopressin
,19695403,C(0.5h),"In the overall patient group, plasma conivaptan concentrations were the highest after the 30-minute (C(0.5h)) loading dose (mean [SD] C(0.5h) = 733 [323] and 701 [343] ng/mL with conivap-tan 20 and 40 mg/d, respectively) and then declined during day 1 to concentrations (C(24h)) (mean [SD] C(24h) = 84 [78] and 215 [129] ng/mL with conivaptan 20 and 40 mg/d, respectively) that were maintained by the continuous infusion of 20 or 40 mg/d.","Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695403/),[ng] / [ml],733,157132,DB00067,Vasopressin
,19695403,C(0.5h),"In the overall patient group, plasma conivaptan concentrations were the highest after the 30-minute (C(0.5h)) loading dose (mean [SD] C(0.5h) = 733 [323] and 701 [343] ng/mL with conivap-tan 20 and 40 mg/d, respectively) and then declined during day 1 to concentrations (C(24h)) (mean [SD] C(24h) = 84 [78] and 215 [129] ng/mL with conivaptan 20 and 40 mg/d, respectively) that were maintained by the continuous infusion of 20 or 40 mg/d.","Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695403/),[ng] / [ml],701,157133,DB00067,Vasopressin
,19695403,C(24h),"In the overall patient group, plasma conivaptan concentrations were the highest after the 30-minute (C(0.5h)) loading dose (mean [SD] C(0.5h) = 733 [323] and 701 [343] ng/mL with conivap-tan 20 and 40 mg/d, respectively) and then declined during day 1 to concentrations (C(24h)) (mean [SD] C(24h) = 84 [78] and 215 [129] ng/mL with conivaptan 20 and 40 mg/d, respectively) that were maintained by the continuous infusion of 20 or 40 mg/d.","Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695403/),[ng] / [ml],84,157134,DB00067,Vasopressin
,19695403,C(24h),"In the overall patient group, plasma conivaptan concentrations were the highest after the 30-minute (C(0.5h)) loading dose (mean [SD] C(0.5h) = 733 [323] and 701 [343] ng/mL with conivap-tan 20 and 40 mg/d, respectively) and then declined during day 1 to concentrations (C(24h)) (mean [SD] C(24h) = 84 [78] and 215 [129] ng/mL with conivaptan 20 and 40 mg/d, respectively) that were maintained by the continuous infusion of 20 or 40 mg/d.","Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695403/),[ng] / [ml],215,157135,DB00067,Vasopressin
,19695403,clearance,"In the pharmacokinetic-rich subset, for conivaptan 20 and 40 mg/d, respectively, conivaptan clearance was 18.7 and 9.5 L/h, the elimination t1/2 was 5.3 and 10.2 hours, and exposure to conivaptan in terms of AUC(infinity) was 6996 and 30,771 ng .","Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695403/),[l] / [h],18.7,157136,DB00067,Vasopressin
,19695403,clearance,"In the pharmacokinetic-rich subset, for conivaptan 20 and 40 mg/d, respectively, conivaptan clearance was 18.7 and 9.5 L/h, the elimination t1/2 was 5.3 and 10.2 hours, and exposure to conivaptan in terms of AUC(infinity) was 6996 and 30,771 ng .","Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695403/),[l] / [h],9.5,157137,DB00067,Vasopressin
,19695403,elimination t1/2,"In the pharmacokinetic-rich subset, for conivaptan 20 and 40 mg/d, respectively, conivaptan clearance was 18.7 and 9.5 L/h, the elimination t1/2 was 5.3 and 10.2 hours, and exposure to conivaptan in terms of AUC(infinity) was 6996 and 30,771 ng .","Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695403/),h,5.3,157138,DB00067,Vasopressin
,19695403,elimination t1/2,"In the pharmacokinetic-rich subset, for conivaptan 20 and 40 mg/d, respectively, conivaptan clearance was 18.7 and 9.5 L/h, the elimination t1/2 was 5.3 and 10.2 hours, and exposure to conivaptan in terms of AUC(infinity) was 6996 and 30,771 ng .","Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695403/),h,10.2,157139,DB00067,Vasopressin
,19695403,AUC(infinity),"In the pharmacokinetic-rich subset, for conivaptan 20 and 40 mg/d, respectively, conivaptan clearance was 18.7 and 9.5 L/h, the elimination t1/2 was 5.3 and 10.2 hours, and exposure to conivaptan in terms of AUC(infinity) was 6996 and 30,771 ng .","Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695403/),ng,6996,157140,DB00067,Vasopressin
,19695403,AUC(infinity),"In the pharmacokinetic-rich subset, for conivaptan 20 and 40 mg/d, respectively, conivaptan clearance was 18.7 and 9.5 L/h, the elimination t1/2 was 5.3 and 10.2 hours, and exposure to conivaptan in terms of AUC(infinity) was 6996 and 30,771 ng .","Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19695403/),ng,"30,771",157141,DB00067,Vasopressin
,9868744,"terminal half-life of elimination (t1/2,)","The terminal half-life of elimination (t1/2,) of desmopressin was calculated to be 2.97 +/- 0.24 (S.E.M.) hr while the clearance was 1.77 +/- 0.10 ml.min.-1.kg-1 and the volume of distribution at steady state was 373 +/- 30 ml.",Pharmacokinetics and antidiuretic effect of intravenous administration of desmopressin in orally overhydrated male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868744/),h,2.97,158258,DB00067,Vasopressin
,9868744,clearance,"The terminal half-life of elimination (t1/2,) of desmopressin was calculated to be 2.97 +/- 0.24 (S.E.M.) hr while the clearance was 1.77 +/- 0.10 ml.min.-1.kg-1 and the volume of distribution at steady state was 373 +/- 30 ml.",Pharmacokinetics and antidiuretic effect of intravenous administration of desmopressin in orally overhydrated male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868744/),[-1·min·ml] / [kg],1.77,158259,DB00067,Vasopressin
,9868744,volume of distribution at steady state,"The terminal half-life of elimination (t1/2,) of desmopressin was calculated to be 2.97 +/- 0.24 (S.E.M.) hr while the clearance was 1.77 +/- 0.10 ml.min.-1.kg-1 and the volume of distribution at steady state was 373 +/- 30 ml.",Pharmacokinetics and antidiuretic effect of intravenous administration of desmopressin in orally overhydrated male volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868744/),ml,373,158260,DB00067,Vasopressin
,9868744,urine osmolality,Four hr after the start of the infusion the mean urine osmolality was 909 +/- 46 mOsm.kg-1.,Pharmacokinetics and antidiuretic effect of intravenous administration of desmopressin in orally overhydrated male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868744/),[mosm] / [kg],909,158261,DB00067,Vasopressin
,7705434,IC50,"YM-26365 inhibited human plasma renin with an IC50 value of 2.9 x 10(-6) M, but did not affect plasma renin from dogs, rabbits, and rats at 10(-4) M. YM-26365 inhibited not only human renin, but also cathepsin D with an IC50 value of 1.7 x 10(-5) M.","Pharmacological properties of YM-26365, a low molecular weight, orally active renin inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705434/),M,2.9 x 10(-6),158654,DB00067,Vasopressin
,7705434,IC50,"YM-26365 inhibited human plasma renin with an IC50 value of 2.9 x 10(-6) M, but did not affect plasma renin from dogs, rabbits, and rats at 10(-4) M. YM-26365 inhibited not only human renin, but also cathepsin D with an IC50 value of 1.7 x 10(-5) M.","Pharmacological properties of YM-26365, a low molecular weight, orally active renin inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705434/),M,1.7 x 10(-5),158655,DB00067,Vasopressin
,7705434,Ki,This compound competitively inhibited the reaction between recombinant human renin and N-acetyl tetradecapeptide with a Ki value of 1.1 x 10(-6) M.,"Pharmacological properties of YM-26365, a low molecular weight, orally active renin inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705434/),M,1.1 x 10(-6),158656,DB00067,Vasopressin
,7705434,Systemic bioavailability,Systemic bioavailability as determined on the basis of the ratio of the total area under the plasma concentration-time curve after 3 mg/kg i.v. and 30 mg/kg orally to rats was 9.6%.,"Pharmacological properties of YM-26365, a low molecular weight, orally active renin inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7705434/),%,9.6,158657,DB00067,Vasopressin
,6818035,Metabolic clearance rate,"Metabolic clearance rate and the volume of fast initial distribution were 287.1 ml min-1 (m2)-1 and 219.3 ml/kg b.w., respectively, in normal subjects.",Metabolic clearance rate of immunoreactive vasopressin in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6818035/),[ml] / [m2·min],287.1,158955,DB00067,Vasopressin
,6818035,volume of fast initial distribution,"Metabolic clearance rate and the volume of fast initial distribution were 287.1 ml min-1 (m2)-1 and 219.3 ml/kg b.w., respectively, in normal subjects.",Metabolic clearance rate of immunoreactive vasopressin in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6818035/),[ml] / [kg],219.3,158956,DB00067,Vasopressin
,2939312,t1/2,"After an intravenous (iv) bolus injection of 100 micrograms alpha h-ANP, levels of immunoreactive alpha h-ANP (IR-alpha hANP) in unextracted plasma fell rapidly and exponentially during the first 10 min (t1/2 = 2.5 min), after which levels declined more slowly to reach basal values 30 min after injection.",Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939312/),min,2.5,161024,DB00067,Vasopressin
,2939312,MCR,Calculated MCR from venous samples was 2.4 L/min and volume of distribution 10.7 L.,Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939312/),[l] / [min],2.4,161025,DB00067,Vasopressin
,2939312,volume of distribution,Calculated MCR from venous samples was 2.4 L/min and volume of distribution 10.7 L.,Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939312/),l,10.7,161026,DB00067,Vasopressin
,2939312,disappearance rate (rapid phase),"After cessation of infusions, the disappearance rate (rapid phase) of IR-alpha hANP was 3.1 min.",Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2939312/),min,3.1,161027,DB00067,Vasopressin
,29745750,flow rate,The chromatographic separation was conducted on an Acquity UPLC BEH™ C18 column with an optimum mobile phase of 10 mM ammonium acetate buffer and 0.1% formic acid in acetonitrile (30:70 v/v) at a flow rate of 0.3 ml/min.,UPLC/MS-MS assay development for estimation of mozavaptan in plasma and its pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29745750/),[ml] / [min],0.3,166710,DB00067,Vasopressin
,9917441,urine production,"Neither nocturnal urine production nor morning urine osmolality after desmopressin injection differed between responders and nonresponders, whereas the responders produced significantly larger amounts of significantly less concentrated urine during the day after the injection compared with the nonresponders (urine production, 2.02 +/- 0.84 and 0.77 +/- 0.20 mL/kg/h; urine osmolality, 558 +/- 271 and 883 +/- 134 mOsm/kg).",Osmoregulation and desmopressin pharmacokinetics in enuretic children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9917441/),[ml] / [h·kg],2.02,169654,DB00067,Vasopressin
,9917441,urine production,"Neither nocturnal urine production nor morning urine osmolality after desmopressin injection differed between responders and nonresponders, whereas the responders produced significantly larger amounts of significantly less concentrated urine during the day after the injection compared with the nonresponders (urine production, 2.02 +/- 0.84 and 0.77 +/- 0.20 mL/kg/h; urine osmolality, 558 +/- 271 and 883 +/- 134 mOsm/kg).",Osmoregulation and desmopressin pharmacokinetics in enuretic children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9917441/),[ml] / [h·kg],0.77,169655,DB00067,Vasopressin
,9917441,urine osmolality,"Neither nocturnal urine production nor morning urine osmolality after desmopressin injection differed between responders and nonresponders, whereas the responders produced significantly larger amounts of significantly less concentrated urine during the day after the injection compared with the nonresponders (urine production, 2.02 +/- 0.84 and 0.77 +/- 0.20 mL/kg/h; urine osmolality, 558 +/- 271 and 883 +/- 134 mOsm/kg).",Osmoregulation and desmopressin pharmacokinetics in enuretic children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9917441/),[mosm] / [kg],558,169656,DB00067,Vasopressin
,9917441,urine osmolality,"Neither nocturnal urine production nor morning urine osmolality after desmopressin injection differed between responders and nonresponders, whereas the responders produced significantly larger amounts of significantly less concentrated urine during the day after the injection compared with the nonresponders (urine production, 2.02 +/- 0.84 and 0.77 +/- 0.20 mL/kg/h; urine osmolality, 558 +/- 271 and 883 +/- 134 mOsm/kg).",Osmoregulation and desmopressin pharmacokinetics in enuretic children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9917441/),[mosm] / [kg],883,169657,DB00067,Vasopressin
,10215955,volume of distribution at steady state (Vss),"The mean increases in the volume of distribution at steady state (Vss) (13.2+/-9.3 dL) and mean residence time (MRT) (4.4+/-3.9 h) between the FVIII-only arm and the FVIII plus Stimate arm were highly significant (P = 0.0015 and P = 0. 0059, respectively).",Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215955/),dl,13.2,171276,DB00067,Vasopressin
,10215955,mean residence time (MRT),"The mean increases in the volume of distribution at steady state (Vss) (13.2+/-9.3 dL) and mean residence time (MRT) (4.4+/-3.9 h) between the FVIII-only arm and the FVIII plus Stimate arm were highly significant (P = 0.0015 and P = 0. 0059, respectively).",Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215955/),h,4.4,171277,DB00067,Vasopressin
,24444280,bleeding times,Median [range] bleeding times were slightly reduced with ticagrelor plus desmopressin compared with ticagrelor alone (7·50 [3-17] vs. 10·50 [3-25] min at 2·5 h).,The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24444280/),min,7·50,173644,DB00067,Vasopressin
,24444280,bleeding times,Median [range] bleeding times were slightly reduced with ticagrelor plus desmopressin compared with ticagrelor alone (7·50 [3-17] vs. 10·50 [3-25] min at 2·5 h).,The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24444280/),min,10·50,173645,DB00067,Vasopressin
,24444280,AUEC,"Co-administration of desmopressin had no impact on IPA, although platelet reactivity was significantly increased (von Willebrand Factor antigen: GLS mean AUEC was 4667%.h for ticagrelor plus desmopressin compared with 2750%.h for ticagrelor alone).",The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24444280/),%·h,4667,173646,DB00067,Vasopressin
,24444280,AUEC,"Co-administration of desmopressin had no impact on IPA, although platelet reactivity was significantly increased (von Willebrand Factor antigen: GLS mean AUEC was 4667%.h for ticagrelor plus desmopressin compared with 2750%.h for ticagrelor alone).",The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24444280/),%·h,2750,173647,DB00067,Vasopressin
,16948809,tmax,RWJ-351647 had a tmax of 1 to 1.1 h and mean half-life of 10.4-17.4 h.,"Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16948809/),h,1 to 1.1,178046,DB00067,Vasopressin
,16948809,half-life,RWJ-351647 had a tmax of 1 to 1.1 h and mean half-life of 10.4-17.4 h.,"Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16948809/),h,10.4-17.4,178047,DB00067,Vasopressin
,10423583,half-maximal effects,"Mean maximum pharmacodynamic activity for both factors was estimated to be three- to four-times higher than baseline activity, and the mean desmopressin concentrations that produce half-maximal effects were approximately 250 to 300 pg/mL.",The pharmacokinetics and pharmacodynamics of desmopressin: effect on plasma factor VIII:C and von Willebrand factor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10423583/),,250 to 300,179011,DB00067,Vasopressin
,18582256,maximum diltiazem concentration,The maximum diltiazem concentration (577 microg.l(-1)) was recorded 7 h post ingestion which was followed by an erratic and prolonged elimination phase.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),[μg] / [l],577,184005,DB00067,Vasopressin
,18582256,maximum clearance,The maximum clearance of diltiazem due to haemoperfusion was calculated to be 19.4 and 15.1 ml.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),ml,19.4,184006,DB00067,Vasopressin
,18582256,maximum clearance,The maximum clearance of diltiazem due to haemoperfusion was calculated to be 19.4 and 15.1 ml.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),ml,15.1,184007,DB00067,Vasopressin
,3711257,half-life,"Plasma DDAVP levels increased in a dose-dependent fashion and its disappearance from the plasma followed an exponential time course, with a half-life 86 to 142 min.",Antidiuretic effect and pharmacokinetics of oral 1-desamino-8-D-arginine vasopressin. 1. Studies in adults and children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3711257/),min,86 to 142,185330,DB00067,Vasopressin
,3711257,urinary osmolality,"In water-loaded adults with central diabetes insipidus (CDI), 200 micrograms oral DDAVP caused marked antidiuresis and mean urinary osmolality increased from 107 mosm/kg to 554 mosm/kg after 3 h.",Antidiuretic effect and pharmacokinetics of oral 1-desamino-8-D-arginine vasopressin. 1. Studies in adults and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3711257/),[mosm] / [kg],107,185331,DB00067,Vasopressin
,3711257,urinary osmolality,"In water-loaded adults with central diabetes insipidus (CDI), 200 micrograms oral DDAVP caused marked antidiuresis and mean urinary osmolality increased from 107 mosm/kg to 554 mosm/kg after 3 h.",Antidiuretic effect and pharmacokinetics of oral 1-desamino-8-D-arginine vasopressin. 1. Studies in adults and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3711257/),[mosm] / [kg],554,185332,DB00067,Vasopressin
,7815278,bioavailabilities,"The use of the bioadhesive starch microsphere delivery system, especially in combination with LPC, had a profound effect on the absorption of desmopressin in sheep, with bioavailabilities reaching nearly 10% compared with 1.2% for a simple nasal solution of desmopressin.",Nasal absorption of desmopressin in rats and sheep. Effect of a bioadhesive microsphere delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7815278/),%,10,186688,DB00067,Vasopressin
,7815278,bioavailabilities,"The use of the bioadhesive starch microsphere delivery system, especially in combination with LPC, had a profound effect on the absorption of desmopressin in sheep, with bioavailabilities reaching nearly 10% compared with 1.2% for a simple nasal solution of desmopressin.",Nasal absorption of desmopressin in rats and sheep. Effect of a bioadhesive microsphere delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7815278/),%,1.2,186689,DB00067,Vasopressin
,12660315,IC50,Compound 1 inhibits oxytocin-evoked intracellular Ca2+ mobilization (IC50 = 8 nM).,"Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12660315/),nM,8,191830,DB00067,Vasopressin
,12660315,pA2,Oxytocininduced contraction of isolated rat uterine strips is blocked by compound 1 (pA2 = 7.82).,"Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12660315/),,7.82,191831,DB00067,Vasopressin
,12660315,ED50,"In anesthetized nonpregnant rats, single administration of compound 1 by i.v. or oral routes causes dose-dependent inhibition of contractions elicited by repeated injections of oxytocin with ED50 = 3.5 mg/kg i.v. and 89 mg/kg p.o., respectively.","Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12660315/),[mg] / [kg],3.5,191832,DB00067,Vasopressin
,12660315,ED50,"In anesthetized nonpregnant rats, single administration of compound 1 by i.v. or oral routes causes dose-dependent inhibition of contractions elicited by repeated injections of oxytocin with ED50 = 3.5 mg/kg i.v. and 89 mg/kg p.o., respectively.","Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12660315/),[mg] / [kg],89,191833,DB00067,Vasopressin
,3669496,clearance,Inulin clearance rose from 110 +/- 14 to 135 +/- 23 ml/min and lithium clearance from 30.9 +/- 7.6 to 48.9 +/- 15.1 ml/min.,Lithium clearance during the paradoxical natriuresis of hypotonic expansion in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3669496/),[ml] / [min],110,194621,DB00067,Vasopressin
,3669496,clearance,Inulin clearance rose from 110 +/- 14 to 135 +/- 23 ml/min and lithium clearance from 30.9 +/- 7.6 to 48.9 +/- 15.1 ml/min.,Lithium clearance during the paradoxical natriuresis of hypotonic expansion in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3669496/),[ml] / [min],135,194622,DB00067,Vasopressin
,3669496,clearance,Inulin clearance rose from 110 +/- 14 to 135 +/- 23 ml/min and lithium clearance from 30.9 +/- 7.6 to 48.9 +/- 15.1 ml/min.,Lithium clearance during the paradoxical natriuresis of hypotonic expansion in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3669496/),[ml] / [min],30.9,194623,DB00067,Vasopressin
,3669496,clearance,Inulin clearance rose from 110 +/- 14 to 135 +/- 23 ml/min and lithium clearance from 30.9 +/- 7.6 to 48.9 +/- 15.1 ml/min.,Lithium clearance during the paradoxical natriuresis of hypotonic expansion in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3669496/),[ml] / [min],48.9,194624,DB00067,Vasopressin
,8858277,constant rate,In the other session a solution of PEG and aprotinin was administered enterally at the constant rate of 5 ml.min-1 for 4 h.,Bioavailability of 1-deamino-8-D-arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8858277/),[ml] / [min],5,195170,DB00067,Vasopressin
,8858277,half-life of elimination,"After i.v. administration, the half-life of elimination of dDAVP was 1.56 h and plasma clearance 1.24 ml.min.",Bioavailability of 1-deamino-8-D-arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8858277/),h,1.56,195171,DB00067,Vasopressin
,8858277,plasma clearance,"After i.v. administration, the half-life of elimination of dDAVP was 1.56 h and plasma clearance 1.24 ml.min.",Bioavailability of 1-deamino-8-D-arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8858277/),min·ml,1.24,195172,DB00067,Vasopressin
,8858277,bioavailability,The mean bioavailability after duodenal administration of dDAVP+ aprotinin was 0.46% compared with 0.09% after duodenal administration of dDAVP alone.,Bioavailability of 1-deamino-8-D-arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8858277/),%,0.46,195173,DB00067,Vasopressin
,8858277,bioavailability,The mean bioavailability after duodenal administration of dDAVP+ aprotinin was 0.46% compared with 0.09% after duodenal administration of dDAVP alone.,Bioavailability of 1-deamino-8-D-arginine vasopressin with an enzyme inhibitor (aprotinin) from the small intestine in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8858277/),%,0.09,195174,DB00067,Vasopressin
,9622556,Ki,"The pyridine N-oxide series is exemplified by L-372,662 (30), which possessed good potency in vitro (Ki = 4.1 nM, cloned human oxytocin receptor) and in vivo (intravenous AD50 = 0.71 mg/kg in the rat), excellent oral bioavailability (90% in the rat, 96% in the dog), good aqueous solubility (>8.5 mg/mL at pH 5.2) which should facilitate formulation for iv administration, and excellent selectivity against the human arginine vasopressin receptors.","Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9622556/),nM,4.1,199232,DB00067,Vasopressin
,9622556,AD50,"The pyridine N-oxide series is exemplified by L-372,662 (30), which possessed good potency in vitro (Ki = 4.1 nM, cloned human oxytocin receptor) and in vivo (intravenous AD50 = 0.71 mg/kg in the rat), excellent oral bioavailability (90% in the rat, 96% in the dog), good aqueous solubility (>8.5 mg/mL at pH 5.2) which should facilitate formulation for iv administration, and excellent selectivity against the human arginine vasopressin receptors.","Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9622556/),[mg] / [kg],0.71,199233,DB00067,Vasopressin
,9622556,oral bioavailability,"The pyridine N-oxide series is exemplified by L-372,662 (30), which possessed good potency in vitro (Ki = 4.1 nM, cloned human oxytocin receptor) and in vivo (intravenous AD50 = 0.71 mg/kg in the rat), excellent oral bioavailability (90% in the rat, 96% in the dog), good aqueous solubility (>8.5 mg/mL at pH 5.2) which should facilitate formulation for iv administration, and excellent selectivity against the human arginine vasopressin receptors.","Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9622556/),%,90,199234,DB00067,Vasopressin
,9622556,oral bioavailability,"The pyridine N-oxide series is exemplified by L-372,662 (30), which possessed good potency in vitro (Ki = 4.1 nM, cloned human oxytocin receptor) and in vivo (intravenous AD50 = 0.71 mg/kg in the rat), excellent oral bioavailability (90% in the rat, 96% in the dog), good aqueous solubility (>8.5 mg/mL at pH 5.2) which should facilitate formulation for iv administration, and excellent selectivity against the human arginine vasopressin receptors.","Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9622556/),%,96,199235,DB00067,Vasopressin
>,9622556,solubility,"The pyridine N-oxide series is exemplified by L-372,662 (30), which possessed good potency in vitro (Ki = 4.1 nM, cloned human oxytocin receptor) and in vivo (intravenous AD50 = 0.71 mg/kg in the rat), excellent oral bioavailability (90% in the rat, 96% in the dog), good aqueous solubility (>8.5 mg/mL at pH 5.2) which should facilitate formulation for iv administration, and excellent selectivity against the human arginine vasopressin receptors.","Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9622556/),[mg] / [ml],8.5,199236,DB00067,Vasopressin
,3942702,duration of effect,The duration of effect was also greatest with that analogue (40-50 min).,Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942702/),min,40-50,200730,DB00067,Vasopressin
,3942702,plasma half-life,Pharmacokinetic studies of intravenous dE-TVT (10 ng/kg body weight) showed that the plasma half-life was approximately 16 min and the clearance 30 l/h.,Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942702/),min,16,200731,DB00067,Vasopressin
,3942702,clearance,Pharmacokinetic studies of intravenous dE-TVT (10 ng/kg body weight) showed that the plasma half-life was approximately 16 min and the clearance 30 l/h.,Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942702/),[l] / [h],30,200732,DB00067,Vasopressin
,3942702,bioavailability,The bioavailability of 100 ng/kg given intranasally was about 5.5%.,Vasotocin analogues which competitively inhibit vasopressin stimulated uterine activity in healthy women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942702/),%,5.5,200733,DB00067,Vasopressin
,8877030,terminal half-lives,"2. Following 20 micrograms IN and 200 micrograms orally, respective plasma DDAVP concentrations peaked after 45.6 +/- 7.3 and 93.3 +/- 3.3 (mean +/- s.e.mean) min, reaching 24.1 +/- 4.7 and 15.1 +/- 3.2 pmol 1(-1) and respective terminal half-lives were 2.2 +/- 0.1 and 2.0 +/- 0.1 h.","Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877030/),h,2.2,209883,DB00067,Vasopressin
,8877030,terminal half-lives,"2. Following 20 micrograms IN and 200 micrograms orally, respective plasma DDAVP concentrations peaked after 45.6 +/- 7.3 and 93.3 +/- 3.3 (mean +/- s.e.mean) min, reaching 24.1 +/- 4.7 and 15.1 +/- 3.2 pmol 1(-1) and respective terminal half-lives were 2.2 +/- 0.1 and 2.0 +/- 0.1 h.","Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidus. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877030/),h,2.0,209884,DB00067,Vasopressin
,216270,PCR,Both the PCR and the apparent initial volume of distribution were significantly greater for AVP than for the biologically inactive iodinated AVP 37.4 +/- 4.8 ml/kg per min vs. 6.7 +/- 0.8 ml/kg per min (P less than 0.001) and 12.7 +/- 0.9% body wt vs. 7.1 +/- 0.4% body wt (P less than 0.001).,Arginine vasopressin metabolism in dogs. I. Evidence for a receptor-mediated mechanism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/216270/),[ml] / [kg·min],37.4,212860,DB00067,Vasopressin
,216270,apparent initial volume of distribution,Both the PCR and the apparent initial volume of distribution were significantly greater for AVP than for the biologically inactive iodinated AVP 37.4 +/- 4.8 ml/kg per min vs. 6.7 +/- 0.8 ml/kg per min (P less than 0.001) and 12.7 +/- 0.9% body wt vs. 7.1 +/- 0.4% body wt (P less than 0.001).,Arginine vasopressin metabolism in dogs. I. Evidence for a receptor-mediated mechanism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/216270/),[ml] / [kg·min],6.7,212861,DB00067,Vasopressin
,216270,apparent initial volume of distribution,Both the PCR and the apparent initial volume of distribution were significantly greater for AVP than for the biologically inactive iodinated AVP 37.4 +/- 4.8 ml/kg per min vs. 6.7 +/- 0.8 ml/kg per min (P less than 0.001) and 12.7 +/- 0.9% body wt vs. 7.1 +/- 0.4% body wt (P less than 0.001).,Arginine vasopressin metabolism in dogs. I. Evidence for a receptor-mediated mechanism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/216270/),%,12.7,212862,DB00067,Vasopressin
,216270,apparent initial volume of distribution,Both the PCR and the apparent initial volume of distribution were significantly greater for AVP than for the biologically inactive iodinated AVP 37.4 +/- 4.8 ml/kg per min vs. 6.7 +/- 0.8 ml/kg per min (P less than 0.001) and 12.7 +/- 0.9% body wt vs. 7.1 +/- 0.4% body wt (P less than 0.001).,Arginine vasopressin metabolism in dogs. I. Evidence for a receptor-mediated mechanism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/216270/),%,7.1,212863,DB00067,Vasopressin
,216270,-,"AVP-PCR was 37.4 +/- 7.1 ml/kg per min at 34 microU/kg per min, which was comparable to that after pulse injection (P less than 0.9).",Arginine vasopressin metabolism in dogs. I. Evidence for a receptor-mediated mechanism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/216270/),[ml] / [kg·min],37.4,212864,DB00067,Vasopressin
,216270,PCR,"AVP-PCR was 37.4 +/- 7.1 ml/kg per min at 34 microU/kg per min, which was comparable to that after pulse injection (P less than 0.9).",Arginine vasopressin metabolism in dogs. I. Evidence for a receptor-mediated mechanism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/216270/),[ml] / [kg·min],37.4,212865,DB00067,Vasopressin
,3281929,relative effectiveness,"It is concluded that the estimated relative effectiveness of intranasally administered SKF 101926 is 3-21%, compared with intravenous administration.",Nasal delivery of a vasopressin antagonist in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3281929/),,3-21,213016,DB00067,Vasopressin
,8238146,t1/2 alpha,Maternal plasma levels of atosiban reached a maximum of 585.2 +/- 82.2 (ng/ml mean +/- SD) at the end of the infusion and decreased biexponentially with a mean t1/2 alpha of 17 minutes and a mean t1/2 beta of 2.2 hours.,Maternal and fetal cardiovascular effects and placental transfer of the oxytocin antagonist atosiban in late-gestation pregnant sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8238146/),min,17,219319,DB00067,Vasopressin
,8238146,t1/2 beta,Maternal plasma levels of atosiban reached a maximum of 585.2 +/- 82.2 (ng/ml mean +/- SD) at the end of the infusion and decreased biexponentially with a mean t1/2 alpha of 17 minutes and a mean t1/2 beta of 2.2 hours.,Maternal and fetal cardiovascular effects and placental transfer of the oxytocin antagonist atosiban in late-gestation pregnant sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8238146/),h,2.2,219320,DB00067,Vasopressin
,18078394,in vivo recovery,The mean in vivo recovery (IU dL(-1) per IU kg(-1)) was 1.9 +/- 0.6 for VWF:RCof; 2.1 +/- 0.6 for VWF:Ag and 2.6 +/- 0.6 for FVIII:C.,"Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18078394/),[iu·iu] / [dl·kg],1.9,219998,DB00067,Vasopressin
,18078394,in vivo recovery,The mean in vivo recovery (IU dL(-1) per IU kg(-1)) was 1.9 +/- 0.6 for VWF:RCof; 2.1 +/- 0.6 for VWF:Ag and 2.6 +/- 0.6 for FVIII:C.,"Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18078394/),[iu·iu] / [dl·kg],2.1,219999,DB00067,Vasopressin
,18078394,in vivo recovery,The mean in vivo recovery (IU dL(-1) per IU kg(-1)) was 1.9 +/- 0.6 for VWF:RCof; 2.1 +/- 0.6 for VWF:Ag and 2.6 +/- 0.6 for FVIII:C.,"Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18078394/),[iu·iu] / [dl·kg],2.6,220000,DB00067,Vasopressin
,18078394,half-life,The mean half-life (h) was 14.4 +/- 10.5 for VWF:RCof; 27.5 +/- 11.0 for VWF:Ag and 33.4 +/- 16.4 for FVIII:C.,"Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18078394/),h,14.4,220001,DB00067,Vasopressin
,18078394,half-life,The mean half-life (h) was 14.4 +/- 10.5 for VWF:RCof; 27.5 +/- 11.0 for VWF:Ag and 33.4 +/- 16.4 for FVIII:C.,"Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18078394/),h,27.5,220002,DB00067,Vasopressin
,18078394,half-life,The mean half-life (h) was 14.4 +/- 10.5 for VWF:RCof; 27.5 +/- 11.0 for VWF:Ag and 33.4 +/- 16.4 for FVIII:C.,"Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18078394/),h,33.4,220003,DB00067,Vasopressin
,15197520,AUC,The mean (95% CI) AUC at night was 302 (272-335) pg x h/ml and in the day was 281 (253-312) pg x h/ml.,Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197520/),[h·pg] / [ml],302,223518,DB00067,Vasopressin
,15197520,AUC,The mean (95% CI) AUC at night was 302 (272-335) pg x h/ml and in the day was 281 (253-312) pg x h/ml.,Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197520/),[h·pg] / [ml],281,223519,DB00067,Vasopressin
,15197520,terminal half-life,"No statistically significant differences were detected between night and day except for terminal half-life, which was 3.1 h at night and 2.8 h in the daytime (P=0.02).",Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197520/),h,3.1,223520,DB00067,Vasopressin
,15197520,terminal half-life,"No statistically significant differences were detected between night and day except for terminal half-life, which was 3.1 h at night and 2.8 h in the daytime (P=0.02).",Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197520/),h,2.8,223521,DB00067,Vasopressin
,15197520,Peak plasma concentration (Cmax),Peak plasma concentration (Cmax) was 6.2 (5.1-7.5) pg/ml at night and 6.6 (5.5-7.9) pg/ml in the daytime.,Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197520/),[pg] / [ml],6.2,223522,DB00067,Vasopressin
,15197520,Peak plasma concentration (Cmax),Peak plasma concentration (Cmax) was 6.2 (5.1-7.5) pg/ml at night and 6.6 (5.5-7.9) pg/ml in the daytime.,Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197520/),[pg] / [ml],6.6,223523,DB00067,Vasopressin
,15197520,time to reach Cmax (tmax),Median time to reach Cmax (tmax) was 1.5 (range 1.0-4.1) h at night and 1.5 (range 0.5-3.0) h in the day.,Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197520/),h,1.5,223524,DB00067,Vasopressin
,15197520,time to reach Cmax (tmax),Median time to reach Cmax (tmax) was 1.5 (range 1.0-4.1) h at night and 1.5 (range 0.5-3.0) h in the day.,Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197520/),h,1.5,223525,DB00067,Vasopressin
,15197520,bioavailability,The bioavailability was 0.08%.,Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15197520/),%,0.08,223526,DB00067,Vasopressin
,24988986,flow rate,"The flow rate was 0.25 mL/min, and total run time was 30 min.",Liquid chromatography-tandem mass spectrometry method for determining tolvaptan and its nine metabolites in rat serum: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24988986/),[ml] / [min],0.25,228793,DB00067,Vasopressin
,24988986,total run time,"The flow rate was 0.25 mL/min, and total run time was 30 min.",Liquid chromatography-tandem mass spectrometry method for determining tolvaptan and its nine metabolites in rat serum: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24988986/),min,30,228794,DB00067,Vasopressin
,1675370,bioavailability,"Plasma DDAVP concentration/time curves conformed closely with zero-order kinetics, which suggests that the bioavailability approached 100%, corresponding to that for direct intravenous infusion.",Administration of antidiuretic peptide (DDAVP) by way of suction de-epithelialised skin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1675370/),%,100,229976,DB00067,Vasopressin
,21853290,elimination half-life,"Following co-administration with grapefruit juice, tolvaptan concentrations were elevated compared with tolvaptan alone for only 16 h postdose; consequently, the mean elimination half-life of tolvaptan was unchanged, 5.7 vs 5.1 h respectively.","Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21853290/),h,5.7,232079,DB00067,Vasopressin
,21853290,elimination half-life,"Following co-administration with grapefruit juice, tolvaptan concentrations were elevated compared with tolvaptan alone for only 16 h postdose; consequently, the mean elimination half-life of tolvaptan was unchanged, 5.7 vs 5.1 h respectively.","Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21853290/),h,5.1,232080,DB00067,Vasopressin
<,24874785,EC50,"We have designed a series of potent oxytocin analogues containing N-alkylglycines in position 7 with excellent selectivity versus the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31 ([2-ThiMeGly(7)]dOT), 47 (carba-6-[Phe(2),BuGly(7)]dOT), 55 (carba-6-[3-MeBzlGly(7)]dOT), and 57 (carba-1-[4-FBzlGly(7)]dOT) have EC50 values at hOTR < 0.1 nM, selectivity ratios versus related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM, and total clearance in rats in the range of 60-80 mL min(-1) kg(-1).","New, potent, and selective peptidic oxytocin receptor agonists. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874785/),nM,0.1,233736,DB00067,Vasopressin
>,24874785,selectivity ratios,"We have designed a series of potent oxytocin analogues containing N-alkylglycines in position 7 with excellent selectivity versus the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31 ([2-ThiMeGly(7)]dOT), 47 (carba-6-[Phe(2),BuGly(7)]dOT), 55 (carba-6-[3-MeBzlGly(7)]dOT), and 57 (carba-1-[4-FBzlGly(7)]dOT) have EC50 values at hOTR < 0.1 nM, selectivity ratios versus related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM, and total clearance in rats in the range of 60-80 mL min(-1) kg(-1).","New, potent, and selective peptidic oxytocin receptor agonists. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874785/),,2000,233737,DB00067,Vasopressin
>,24874785,IC50,"We have designed a series of potent oxytocin analogues containing N-alkylglycines in position 7 with excellent selectivity versus the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31 ([2-ThiMeGly(7)]dOT), 47 (carba-6-[Phe(2),BuGly(7)]dOT), 55 (carba-6-[3-MeBzlGly(7)]dOT), and 57 (carba-1-[4-FBzlGly(7)]dOT) have EC50 values at hOTR < 0.1 nM, selectivity ratios versus related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM, and total clearance in rats in the range of 60-80 mL min(-1) kg(-1).","New, potent, and selective peptidic oxytocin receptor agonists. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874785/),nM,500,233738,DB00067,Vasopressin
,24874785,total clearance,"We have designed a series of potent oxytocin analogues containing N-alkylglycines in position 7 with excellent selectivity versus the related V1a, V1b, and V2 vasopressin receptors and short half-life: agonists 31 ([2-ThiMeGly(7)]dOT), 47 (carba-6-[Phe(2),BuGly(7)]dOT), 55 (carba-6-[3-MeBzlGly(7)]dOT), and 57 (carba-1-[4-FBzlGly(7)]dOT) have EC50 values at hOTR < 0.1 nM, selectivity ratios versus related human vasopressin receptors of >2000, IC50 at hV1aR > 500 nM, and total clearance in rats in the range of 60-80 mL min(-1) kg(-1).","New, potent, and selective peptidic oxytocin receptor agonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874785/),[ml] / [kg·min],60-80,233739,DB00067,Vasopressin
,31037429,time-to-maximum concentration (Tmax),AV002 intranasal administration produced a time-to-maximum concentration (Tmax) between 15 and 30 min and a maximum concentration (Cmax) <10 pg/mL.,Pharmacokinetic and Pharmacodynamic Properties of a Micro-Dose Nasal Spray Formulation of Desmopressin (AV002) in Healthy Water-Loaded Subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31037429/),min,15 and 30,234248,DB00067,Vasopressin
<,31037429,maximum concentration (Cmax),AV002 intranasal administration produced a time-to-maximum concentration (Tmax) between 15 and 30 min and a maximum concentration (Cmax) <10 pg/mL.,Pharmacokinetic and Pharmacodynamic Properties of a Micro-Dose Nasal Spray Formulation of Desmopressin (AV002) in Healthy Water-Loaded Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31037429/),[pg] / [ml],10,234249,DB00067,Vasopressin
,31037429,Bioavailability,Bioavailability of AV002 was approximately 8% compared to SC injection.,Pharmacokinetic and Pharmacodynamic Properties of a Micro-Dose Nasal Spray Formulation of Desmopressin (AV002) in Healthy Water-Loaded Subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31037429/),%,8,234250,DB00067,Vasopressin
,31037429,urine osmolality,AV002 2.0 μg had maximum median urine osmolality of 629 mOsm/kg and median urine output ≤2 mL/min for 5-6 h.,Pharmacokinetic and Pharmacodynamic Properties of a Micro-Dose Nasal Spray Formulation of Desmopressin (AV002) in Healthy Water-Loaded Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31037429/),[mosm] / [kg],629,234251,DB00067,Vasopressin
≤,31037429,urine output,AV002 2.0 μg had maximum median urine osmolality of 629 mOsm/kg and median urine output ≤2 mL/min for 5-6 h.,Pharmacokinetic and Pharmacodynamic Properties of a Micro-Dose Nasal Spray Formulation of Desmopressin (AV002) in Healthy Water-Loaded Subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31037429/),[ml] / [min],2,234252,DB00067,Vasopressin
,6685489,bioavailability,The bioavailability of IS-2-MN in the rat was 100%.,"[Comparative antianginal, hemodynamic and pharmacokinetic effects of isosorbide-2-mononitrate and isosorbide dinitrate in the rat]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6685489/),%,100,234412,DB00067,Vasopressin
,12395330,daily urine output,"VPA produced a significant dose-related increase in daily urine output (1,454 +/- 858 mL to 4,568 +/- 4,385 mL with VPA 300 mg) and a dose-related decrease in urine osmolality.",Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395330/),ml,"1,454",235234,DB00067,Vasopressin
,12395330,daily urine output,"VPA produced a significant dose-related increase in daily urine output (1,454 +/- 858 mL to 4,568 +/- 4,385 mL with VPA 300 mg) and a dose-related decrease in urine osmolality.",Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395330/),ml,"4,568",235235,DB00067,Vasopressin
greater,12395330,free water clearance,The free water clearance reached greater than 3 mL/min for doses 100 mg or greater.,Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395330/),[ml] / [min],3,235236,DB00067,Vasopressin
,12395330,Elimination half-life,Elimination half-life ranged from 9.0 hours after 100 mg to 22.6 hours after 200 mg.,Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395330/),h,9.0,235237,DB00067,Vasopressin
,12395330,Elimination half-life,Elimination half-life ranged from 9.0 hours after 100 mg to 22.6 hours after 200 mg.,Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12395330/),h,22.6,235238,DB00067,Vasopressin
,3709077,maximum increase in C water (delta C water max.),"The maximum increase in C water (delta C water max.) was 1.07 ml/min (median) before remission and 7.93 ml/min after, compared with 8.01 ml/min in the control group.","Renal water excretion before and after remission of nephrotic syndrome: relationship between free water clearance and kidney function, arginine vasopressin, angiotensin II and aldosterone in plasma before and after oral water loading. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709077/),[ml] / [min],1.07,235943,DB00067,Vasopressin
,3709077,maximum increase in C water (delta C water max.),"The maximum increase in C water (delta C water max.) was 1.07 ml/min (median) before remission and 7.93 ml/min after, compared with 8.01 ml/min in the control group.","Renal water excretion before and after remission of nephrotic syndrome: relationship between free water clearance and kidney function, arginine vasopressin, angiotensin II and aldosterone in plasma before and after oral water loading. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709077/),[ml] / [min],7.93,235944,DB00067,Vasopressin
,3709077,maximum increase in C water (delta C water max.),"The maximum increase in C water (delta C water max.) was 1.07 ml/min (median) before remission and 7.93 ml/min after, compared with 8.01 ml/min in the control group.","Renal water excretion before and after remission of nephrotic syndrome: relationship between free water clearance and kidney function, arginine vasopressin, angiotensin II and aldosterone in plasma before and after oral water loading. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709077/),[ml] / [min],8.01,235945,DB00067,Vasopressin
,3709077,A,AVP was higher in the nephrotic syndrome both before (2.9 pmol/l) and after remission (2.9 pmol/l) compared with the control group (1.8 pmol/l).,"Renal water excretion before and after remission of nephrotic syndrome: relationship between free water clearance and kidney function, arginine vasopressin, angiotensin II and aldosterone in plasma before and after oral water loading. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709077/),[pM] / [l],2.9,235946,DB00067,Vasopressin
,3709077,A,AVP was higher in the nephrotic syndrome both before (2.9 pmol/l) and after remission (2.9 pmol/l) compared with the control group (1.8 pmol/l).,"Renal water excretion before and after remission of nephrotic syndrome: relationship between free water clearance and kidney function, arginine vasopressin, angiotensin II and aldosterone in plasma before and after oral water loading. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709077/),[pM] / [l],1.8,235947,DB00067,Vasopressin
,20017819,plasma concentration,"After IV administration, the plasma concentration of methadone at 10 minutes was 82.1 +/- 9.2 ng mL(-1) (mean +/- SD), the terminal half-life was 3.9 +/- 1.0 hours, the volume of distribution 9.2 +/- 3.3 L kg(-1) and plasma clearance 27.9 +/- 7.6 mL minute(-1) kg(-1).",Clinical pharmacology of methadone in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),[ng] / [ml],82.1,236919,DB00067,Vasopressin
,20017819,terminal half-life,"After IV administration, the plasma concentration of methadone at 10 minutes was 82.1 +/- 9.2 ng mL(-1) (mean +/- SD), the terminal half-life was 3.9 +/- 1.0 hours, the volume of distribution 9.2 +/- 3.3 L kg(-1) and plasma clearance 27.9 +/- 7.6 mL minute(-1) kg(-1).",Clinical pharmacology of methadone in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),h,3.9,236920,DB00067,Vasopressin
,20017819,volume of distribution,"After IV administration, the plasma concentration of methadone at 10 minutes was 82.1 +/- 9.2 ng mL(-1) (mean +/- SD), the terminal half-life was 3.9 +/- 1.0 hours, the volume of distribution 9.2 +/- 3.3 L kg(-1) and plasma clearance 27.9 +/- 7.6 mL minute(-1) kg(-1).",Clinical pharmacology of methadone in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),[l] / [kg],9.2,236921,DB00067,Vasopressin
,20017819,plasma clearance,"After IV administration, the plasma concentration of methadone at 10 minutes was 82.1 +/- 9.2 ng mL(-1) (mean +/- SD), the terminal half-life was 3.9 +/- 1.0 hours, the volume of distribution 9.2 +/- 3.3 L kg(-1) and plasma clearance 27.9 +/- 7.6 mL minute(-1) kg(-1).",Clinical pharmacology of methadone in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),[ml] / [kg·minute],27.9,236922,DB00067,Vasopressin
,20017819,time to maximal plasma concentration,"After SC administration, time to maximal plasma concentration was 1.26 +/- 1.04 hours and maximal plasma concentration of methadone was 23.9 +/- 14.4 ng mL(-1), the terminal half-life was 10.7 +/- 4.3 hours and bioavailability was 79 +/- 22%.",Clinical pharmacology of methadone in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),h,1.26,236923,DB00067,Vasopressin
,20017819,maximal plasma concentration,"After SC administration, time to maximal plasma concentration was 1.26 +/- 1.04 hours and maximal plasma concentration of methadone was 23.9 +/- 14.4 ng mL(-1), the terminal half-life was 10.7 +/- 4.3 hours and bioavailability was 79 +/- 22%.",Clinical pharmacology of methadone in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),[ng] / [ml],23.9,236924,DB00067,Vasopressin
,20017819,terminal half-life,"After SC administration, time to maximal plasma concentration was 1.26 +/- 1.04 hours and maximal plasma concentration of methadone was 23.9 +/- 14.4 ng mL(-1), the terminal half-life was 10.7 +/- 4.3 hours and bioavailability was 79 +/- 22%.",Clinical pharmacology of methadone in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),h,10.7,236925,DB00067,Vasopressin
,20017819,bioavailability,"After SC administration, time to maximal plasma concentration was 1.26 +/- 1.04 hours and maximal plasma concentration of methadone was 23.9 +/- 14.4 ng mL(-1), the terminal half-life was 10.7 +/- 4.3 hours and bioavailability was 79 +/- 22%.",Clinical pharmacology of methadone in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20017819/),%,79,236926,DB00067,Vasopressin
,3760747,Half-lives,"Half-lives based on the disappearance of [3H]9-desglycinamide,8-arginine vasopressin ([3H]DGAVP) following in-vitro incubation in plasma were 1.7 h (dog), 5.8 h (rat) and greater than 12 h (man).","[3H]9-desglycinamide,8-arginine vasopressin: metabolism and in-vivo fate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760747/),h,1.7,237948,DB00067,Vasopressin
,3760747,Half-lives,"Half-lives based on the disappearance of [3H]9-desglycinamide,8-arginine vasopressin ([3H]DGAVP) following in-vitro incubation in plasma were 1.7 h (dog), 5.8 h (rat) and greater than 12 h (man).","[3H]9-desglycinamide,8-arginine vasopressin: metabolism and in-vivo fate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760747/),h,5.8,237949,DB00067,Vasopressin
greater,3760747,Half-lives,"Half-lives based on the disappearance of [3H]9-desglycinamide,8-arginine vasopressin ([3H]DGAVP) following in-vitro incubation in plasma were 1.7 h (dog), 5.8 h (rat) and greater than 12 h (man).","[3H]9-desglycinamide,8-arginine vasopressin: metabolism and in-vivo fate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760747/),h,12,237950,DB00067,Vasopressin
,3760747,half-lives,Disappearance of [3H]DGAVP from rat blood after a single i.v. injection followed a biphasic decay with half-lives of 2.2 +/- 0.8 (S.D.) min (distribution phase) and 14.4 +/- 1.2 min (elimination phase).,"[3H]9-desglycinamide,8-arginine vasopressin: metabolism and in-vivo fate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760747/),min,2.2,237951,DB00067,Vasopressin
,3760747,half-lives,Disappearance of [3H]DGAVP from rat blood after a single i.v. injection followed a biphasic decay with half-lives of 2.2 +/- 0.8 (S.D.) min (distribution phase) and 14.4 +/- 1.2 min (elimination phase).,"[3H]9-desglycinamide,8-arginine vasopressin: metabolism and in-vivo fate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760747/),min,14.4,237952,DB00067,Vasopressin
,3760747,central,"The central and peripheral volumes of distribution were high and of the same order of magnitude, being 0.21 and 0.25 litres/kg respectively.","[3H]9-desglycinamide,8-arginine vasopressin: metabolism and in-vivo fate. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760747/),[l] / [kg],0.21,237953,DB00067,Vasopressin
,3760747,peripheral volumes of distribution,"The central and peripheral volumes of distribution were high and of the same order of magnitude, being 0.21 and 0.25 litres/kg respectively.","[3H]9-desglycinamide,8-arginine vasopressin: metabolism and in-vivo fate. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760747/),[l] / [kg],0.25,237954,DB00067,Vasopressin
,3760747,Blood clearance,Blood clearance values ranged from 36 to 45 ml/min per kg.,"[3H]9-desglycinamide,8-arginine vasopressin: metabolism and in-vivo fate. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760747/),[ml] / [kg·min],36 to 45,237955,DB00067,Vasopressin
,3760747,terminal half-lives,"Maximal concentrations were reached at 7.5 min, whereafter they declined bi-exponentially with terminal half-lives of 31.1 +/- 8.7 min.","[3H]9-desglycinamide,8-arginine vasopressin: metabolism and in-vivo fate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760747/),min,31.1,237956,DB00067,Vasopressin
,3760747,bioavailability,"The mean bioavailability for DGAVP was almost 100%, demonstrating virtually complete absorption from the s.c. injection site.","[3H]9-desglycinamide,8-arginine vasopressin: metabolism and in-vivo fate. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3760747/),%,100,237957,DB00067,Vasopressin
,2339105,plasma mean residence time (MRT),"Plasma kinetics of DGAVP were shown to be linear within the dose range studied (50-150 micrograms), plasma mean residence time (MRT) being 18 +/- 4 min (mean +/- SE; n = 9).",Transport of desglycinamide-arginine vasopressin across the blood-brain barrier in rats as evaluated by the unit impulse response methodology. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2339105/),min,18,239002,DB00067,Vasopressin
,2339105,MRT,"Elimination of DGAVP from CSF after icv administration was linear, with an MRT of 10 +/- 1 min (n = 9).",Transport of desglycinamide-arginine vasopressin across the blood-brain barrier in rats as evaluated by the unit impulse response methodology. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2339105/),min,10,239003,DB00067,Vasopressin
,2339105,BBB transport clearance,"The BBB transport clearance value was 1.0 +/- 0.3 microliters/min, and 0.026 +/- 0.007% of the administered dose was transported into the central nervous system.",Transport of desglycinamide-arginine vasopressin across the blood-brain barrier in rats as evaluated by the unit impulse response methodology. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2339105/),[μl] / [min],1.0,239004,DB00067,Vasopressin
,3443952,clearance,A maximal effect was induced by a dose of 30 pmol h-1 100 g body weight-1 which decreased inulin clearance from 3.23 +/- 0.76 (mean +/- S.E. of mean) to 1.60 +/- 0.37 ml/min (P less than 0.02).,Renal haemodynamic actions of pressor doses of lysine vasopressin in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443952/),[ml] / [min],3.23,244575,DB00067,Vasopressin
,3443952,clearance,A maximal effect was induced by a dose of 30 pmol h-1 100 g body weight-1 which decreased inulin clearance from 3.23 +/- 0.76 (mean +/- S.E. of mean) to 1.60 +/- 0.37 ml/min (P less than 0.02).,Renal haemodynamic actions of pressor doses of lysine vasopressin in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443952/),[ml] / [min],1.60,244576,DB00067,Vasopressin
,3443952,clearance,"A change in inulin clearance (from 3.42 +/- 0.46 to 2.17 +/- 0.33 ml/min, P less than 0.01) was also observed in rats pre-treated with indomethacin and infused with vasopressin at the same dose.",Renal haemodynamic actions of pressor doses of lysine vasopressin in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443952/),[ml] / [min],3.42,244577,DB00067,Vasopressin
,3443952,clearance,"A change in inulin clearance (from 3.42 +/- 0.46 to 2.17 +/- 0.33 ml/min, P less than 0.01) was also observed in rats pre-treated with indomethacin and infused with vasopressin at the same dose.",Renal haemodynamic actions of pressor doses of lysine vasopressin in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443952/),[ml] / [min],2.17,244578,DB00067,Vasopressin
,23471831,half-life (T½ ),"Plasma pharmacokinetics findings showed a half-life (T½ ) of 2 and 6 h in rat and dog, respectively.",Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471831/),h,2,244661,DB00067,Vasopressin
,23471831,half-life (T½ ),"Plasma pharmacokinetics findings showed a half-life (T½ ) of 2 and 6 h in rat and dog, respectively.",Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471831/),h,6,244662,DB00067,Vasopressin
,23471831,T½,Rat brain levels following a single oral dose were approximately 20% of plasma values with a T½ of 6 h.,Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23471831/),h,6,244663,DB00067,Vasopressin
>,22239250,pK(i),SAR studies involving mono- and disubstitution in the 3'-pyridyl ring and variation of the 3-isobutyl group gave potent compounds (pK(i) > 9.0) with good aqueous solubility.,"Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22239250/),,9.0,250128,DB00067,Vasopressin
,22239250,pK(i),"Evaluation of the pharmacokinetic profile in the rat, dog, and cynomolgus monkey of those derivatives with low cynomolgus monkey and human intrinsic clearance gave 2',6'-dimethyl-3'-pyridyl R-sec-butyl morpholine amide Epelsiban (69), a highly potent oxytocin antagonist (pK(i) = 9.9) with >31000-fold selectivity over all three human vasopressin receptors hV1aR, hV2R, and hV1bR, with no significant P450 inhibition.","Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22239250/),,9.9,250129,DB00067,Vasopressin
,22239250,bioavailability,"Epelsiban has low levels of intrinsic clearance against the microsomes of four species, good bioavailability (55%) and comparable potency to atosiban in the rat, but is 100-fold more potent than the latter in vitro and was negative in the genotoxicity screens with a satisfactory oral safety profile in female rats.","Pyridyl-2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists: synthesis, pharmacokinetics, and in vivo potency. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22239250/),%,55,250130,DB00067,Vasopressin
,8321918,VE,"In adequately hydrated rabbits, the infusion of AVP generated plasma levels of 35 +/- 7 pg/ml; the VE decreased from 204 +/- 23 to 111 +/- 10 ml/kg (p < 0.01) because of a decrease in plasma (VP) and interstitial volumes (VI).",Water and sodium homeostasis in conscious rabbits: role of arginine-vasopressin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321918/),[ml] / [kg],204,254510,DB00067,Vasopressin
,8321918,VE,"In adequately hydrated rabbits, the infusion of AVP generated plasma levels of 35 +/- 7 pg/ml; the VE decreased from 204 +/- 23 to 111 +/- 10 ml/kg (p < 0.01) because of a decrease in plasma (VP) and interstitial volumes (VI).",Water and sodium homeostasis in conscious rabbits: role of arginine-vasopressin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8321918/),[ml] / [kg],111,254511,DB00067,Vasopressin
,14681716,Plasma osmolality,"Plasma osmolality increased from 285+/-1 to 296+/-1 mosm/kg (P<0.001 during hyperosmolality, and decreased from 286+/-1 to 265+/-1 mosm/kg during hypo-osmolality (P<0.001).","Effects of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681716/),[mosm] / [kg],285,255761,DB00067,Vasopressin
,14681716,Plasma osmolality,"Plasma osmolality increased from 285+/-1 to 296+/-1 mosm/kg (P<0.001 during hyperosmolality, and decreased from 286+/-1 to 265+/-1 mosm/kg during hypo-osmolality (P<0.001).","Effects of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681716/),[mosm] / [kg],296,255762,DB00067,Vasopressin
,14681716,Plasma osmolality,"Plasma osmolality increased from 285+/-1 to 296+/-1 mosm/kg (P<0.001 during hyperosmolality, and decreased from 286+/-1 to 265+/-1 mosm/kg during hypo-osmolality (P<0.001).","Effects of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681716/),[mosm] / [kg],286,255763,DB00067,Vasopressin
,14681716,Plasma osmolality,"Plasma osmolality increased from 285+/-1 to 296+/-1 mosm/kg (P<0.001 during hyperosmolality, and decreased from 286+/-1 to 265+/-1 mosm/kg during hypo-osmolality (P<0.001).","Effects of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681716/),[mosm] / [kg],265,255764,DB00067,Vasopressin
,1672843,time of peak plasma drug concentration,"Maximum reduction in ST-segment depression was found 4 and 8 h after IS-5-MN intake both after one-week and long-term therapy at the time of peak plasma drug concentration (341 +/- 95 and 405 +/- 125 ng/ml, respectively).","Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),[ng] / [ml],341,256101,DB00067,Vasopressin
,1672843,time of peak plasma drug concentration,"Maximum reduction in ST-segment depression was found 4 and 8 h after IS-5-MN intake both after one-week and long-term therapy at the time of peak plasma drug concentration (341 +/- 95 and 405 +/- 125 ng/ml, respectively).","Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),[ng] / [ml],405,256102,DB00067,Vasopressin
below,1672843,residual plasma concentration,"At a residual plasma concentration below 100 ng/ml, ST depression was not significantly improved 24 h after drug intake compared with placebo.","Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),,100,256103,DB00067,Vasopressin
,1672843,Maximum IS-5-MN plasma concentrations,Maximum IS-5-MN plasma concentrations at a mean of 445 +/- 116 ng/ml were reached after 5.8 +/- 2.9 h.,"Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),[ng] / [ml],445,256104,DB00067,Vasopressin
,1672843,Beta-phase half-life of elimination,Beta-phase half-life of elimination was 9 +/- 3 h.,"Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),h,9,256105,DB00067,Vasopressin
,6254359,maximal urinary osmolality,Indomethacin was associated with a significant increase in maximal urinary osmolality from 826 +/- 47 mosmol/kg H2) to 920 +/- 32 mosmol/kg H2O (P < 0.01).,The role of the prostaglandin system in the regulation of renal function in normal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[mosmol] / [h2·kg],826,257963,DB00067,Vasopressin
,6254359,maximal urinary osmolality,Indomethacin was associated with a significant increase in maximal urinary osmolality from 826 +/- 47 mosmol/kg H2) to 920 +/- 32 mosmol/kg H2O (P < 0.01).,The role of the prostaglandin system in the regulation of renal function in normal women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[mosmol] / [h2o·kg],920,257964,DB00067,Vasopressin
,6254359,"Minimal ""free water"" clearance","Minimal ""free water"" clearance was -1.40 +/- 0.02 ml/min before and -1.63 +/- 0.04 ml/min (P < 0.01) after the administration of indomethacin.",The role of the prostaglandin system in the regulation of renal function in normal women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[ml] / [min],-1.40,257965,DB00067,Vasopressin
,6254359,"Minimal ""free water"" clearance","Minimal ""free water"" clearance was -1.40 +/- 0.02 ml/min before and -1.63 +/- 0.04 ml/min (P < 0.01) after the administration of indomethacin.",The role of the prostaglandin system in the regulation of renal function in normal women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[ml] / [min],-,257966,DB00067,Vasopressin
,6254359,"Minimal ""free water"" clearance","Minimal ""free water"" clearance was -1.40 +/- 0.02 ml/min before and -1.63 +/- 0.04 ml/min (P < 0.01) after the administration of indomethacin.",The role of the prostaglandin system in the regulation of renal function in normal women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6254359/),[ml] / [min],1.63,257967,DB00067,Vasopressin
,2156886,MCR,"The MCR and plasma half-life of BNP were 2.69 L/min and 3.1 min, respectively.",Brain natriuretic peptide administered to man: actions and metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2156886/),[l] / [min],2.69,260878,DB00067,Vasopressin
,2156886,plasma half-life,"The MCR and plasma half-life of BNP were 2.69 L/min and 3.1 min, respectively.",Brain natriuretic peptide administered to man: actions and metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2156886/),min,3.1,260879,DB00067,Vasopressin
,8437126,urinary excretion,The 24-h urinary excretion ranged from 14.3 to 25.6% of the i.v. dose and was negatively correlated with peptide lipophilicity.,Pharmacokinetic and pharmacologic properties of antiuterotonic oxytocin analogs in the rat. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8437126/),%,14.3 to 25.6,261281,DB00067,Vasopressin
,8222299,clearance,"The clearance of antocin was 23.5 +/- 7.6 l/h, the volume of distribution was 13.1 +/- 3.8 l and the biological half-life was 39.0 +/- 4.1 minutes.","Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222299/),[l] / [h],23.5,261775,DB00067,Vasopressin
,8222299,volume of distribution,"The clearance of antocin was 23.5 +/- 7.6 l/h, the volume of distribution was 13.1 +/- 3.8 l and the biological half-life was 39.0 +/- 4.1 minutes.","Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222299/),l,13.1,261776,DB00067,Vasopressin
,8222299,biological half-life,"The clearance of antocin was 23.5 +/- 7.6 l/h, the volume of distribution was 13.1 +/- 3.8 l and the biological half-life was 39.0 +/- 4.1 minutes.","Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8222299/),min,39.0,261777,DB00067,Vasopressin
,24337978,time to reach Cmax (tmax),"Peak plasma concentrations (Cmax) of QGC001 and EC33 increased linearly with the dose, with a median time to reach Cmax (tmax) of 1.5 h for QGC001 and 3.0 h for EC33.","Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24337978/),h,1.5,265544,DB00067,Vasopressin
,24337978,time to reach Cmax (tmax),"Peak plasma concentrations (Cmax) of QGC001 and EC33 increased linearly with the dose, with a median time to reach Cmax (tmax) of 1.5 h for QGC001 and 3.0 h for EC33.","Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24337978/),h,3.0,265545,DB00067,Vasopressin
,24337978,plasma elimination half-life,The median plasma elimination half-life of QGC001 was 1.6 h consistently throughout doses.,"Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24337978/),h,1.6,265546,DB00067,Vasopressin
,8435898,half-life of elimination (t1/2),"After intravenous administration, the half-life of elimination (t1/2) of dDAVP was 78 +/- 10 minutes.",Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8435898/),min,78,267775,DB00067,Vasopressin
,8435898,bioavailability,"Using the area under the curve of dDAVP from the subcutaneous administration as a reference, bioavailability was found to be 3.4% after intranasal administration and 0.1% after oral administration.",Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8435898/),%,3.4,267776,DB00067,Vasopressin
,8435898,bioavailability,"Using the area under the curve of dDAVP from the subcutaneous administration as a reference, bioavailability was found to be 3.4% after intranasal administration and 0.1% after oral administration.",Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8435898/),%,0.1,267777,DB00067,Vasopressin
,21626284,duration of,"The duration of antidiuretic action was 4, 8 and 11 h, respectively, for 125, 250, and 500 ng, increasing from 250 to 500 ng but for the remaining secondary dynamic efficacy parameters no difference could be detected based on descriptive statistics between the doses 250 and 500 ng, indicating that the upper plateau region of the dose-response curve had been reached.",Desmopressin duration of antidiuretic action in patients with central diabetes insipidus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21626284/),h,4,269296,DB00067,Vasopressin
,21626284,duration of,"The duration of antidiuretic action was 4, 8 and 11 h, respectively, for 125, 250, and 500 ng, increasing from 250 to 500 ng but for the remaining secondary dynamic efficacy parameters no difference could be detected based on descriptive statistics between the doses 250 and 500 ng, indicating that the upper plateau region of the dose-response curve had been reached.",Desmopressin duration of antidiuretic action in patients with central diabetes insipidus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21626284/),h,8,269297,DB00067,Vasopressin
,21626284,duration of,"The duration of antidiuretic action was 4, 8 and 11 h, respectively, for 125, 250, and 500 ng, increasing from 250 to 500 ng but for the remaining secondary dynamic efficacy parameters no difference could be detected based on descriptive statistics between the doses 250 and 500 ng, indicating that the upper plateau region of the dose-response curve had been reached.",Desmopressin duration of antidiuretic action in patients with central diabetes insipidus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21626284/),h,11,269298,DB00067,Vasopressin
,16047145,complete response,One complete response (54.1+ months) and 2 partial responses were observed.,Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),month,54,269519,DB00067,Vasopressin
,16047145,Time to progression,"Time to progression was 4.4 months (0.8-54.1+), and median survival was 8.0 months (0.8-54.1+).",Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),month,4.4,269520,DB00067,Vasopressin
,16047145,survival,"Time to progression was 4.4 months (0.8-54.1+), and median survival was 8.0 months (0.8-54.1+).",Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),month,8.0,269521,DB00067,Vasopressin
,16047145,Cmax,"There was a significant reduction of 5-FU Cmax in plasma the second day of treatment if vasopressin was used (3.4+/-2.5 and 6.1+/-5.4 mumol/l, respectively, p<0.05).",Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),[μM] / [l],3.4,269522,DB00067,Vasopressin
,16047145,Cmax,"There was a significant reduction of 5-FU Cmax in plasma the second day of treatment if vasopressin was used (3.4+/-2.5 and 6.1+/-5.4 mumol/l, respectively, p<0.05).",Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),[μM] / [l],6.1,269523,DB00067,Vasopressin
,16047145,Tumour response,Tumour response was 4.4% and median survival time 8.0 months.,Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),%,4.4,269524,DB00067,Vasopressin
,16047145,survival time,Tumour response was 4.4% and median survival time 8.0 months.,Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16047145/),month,8.0,269525,DB00067,Vasopressin
,34176392,bioavailability,Absolute balovaptan bioavailability was high (103-116%).,"Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34176392/),%,103-116,272660,DB00067,Vasopressin
,34176392,half-life,"Steady-state (Day 14) balovaptan PK was approximately dose proportional with a half-life of 45-47 hours, but single-dose Cmax increased more than dose proportionally and half-life was inversely dose-proportional - a discordance partially attributable to a dose-and-time-dependent volume of distribution.","Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34176392/),h,45-47,272661,DB00067,Vasopressin
,8126695,IC50,A number of analogues in the TP series that incorporate a modified or unmodified L-methionine sulfone amide at the C2 endo position on the camphor ring exhibit high affinity for OT receptors (IC50 = 1.3-15 nM) and good selectivity for binding to OT versus arginine vasopressin V1a and V2 receptors.,"1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),nM,1.3-15,274111,DB00067,Vasopressin
,8126695,IC50,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),nM,8.9,274112,DB00067,Vasopressin
,8126695,IC50,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),nM,26,274113,DB00067,Vasopressin
,8126695,oral bioavailability,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),%,35,274114,DB00067,Vasopressin
,8126695,oral bioavailability,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),%,25,274115,DB00067,Vasopressin
,8126695,oral bioavailability,"Compound 7 (L-368,899) exhibited the best overall profile of OT receptor affinity (IC50 = 8.9 nM, rat uterus; 26 nM, human uterus), potency for inhibition of OT-stimulated contractions of the isolated rat uterus (pA2 = 8.9) and in situ rat uterus (AD50 = 0.35 mg/kg after intravenous (i.v.) administration and 7.0 mg/kg after intraduodenal administration), aqueous solubility (3.7 mg/mL at pH 5.0), and oral bioavailability in several species (35% (rat), 25% (dog), and 21% (chimpanzee) as estimated from radioreceptor determination of drug levels in plasma after oral and i.v. dosing).","1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126695/),%,21,274116,DB00067,Vasopressin
